{"transactions":[{"id":673730,"issuer":{"id":9529,"kind":"organization","name":"Forte Biosciences, Inc."},"owners":[{"id":19063,"kind":"person","name":"Kornfeld Steven","position":1,"cik":"0001814653","reported_name":"Kornfeld Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2026-08-27T20:36:10.000Z","date":"2026-08-27","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":18353,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Forte Biosciences, Inc. (the \"Issuer\") Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, each outstanding restricted stock unit (a \"Company RSU\"), whether or not vested, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the Merger Consideration, multiplied by (y) the total number of shares subject to such Company RSU immediately prior to the effective time of the Merger."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, each outstanding restricted stock unit (a \"Company RSU\"), whether or not vested, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the Merger Consideration, multiplied by (y) the total number of shares subject to such Company RSU immediately prior to the effective time of the Merger."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the Merger Agreement, each outstanding restricted stock unit (a \"Company RSU\"), whether or not vested, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the Merger Consideration, multiplied by (y) the total number of shares subject to such Company RSU immediately prior to the effective time of the Merger."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":18353},"source":{"system":"sec-edgar","filing":"0001814653-26-000003","document":"form4-08272026_080806.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1419041/000181465326000003/form4-08272026_080806.xml","form_type":"4"}},{"id":673729,"issuer":{"id":9529,"kind":"organization","name":"Forte Biosciences, Inc."},"owners":[{"id":19063,"kind":"person","name":"Kornfeld Steven","position":1,"cik":"0001814653","reported_name":"Kornfeld Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-08-27T20:36:10.000Z","date":"2026-08-27","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":31000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, each unexercised and outstanding option to purchase shares of Common Stock (a \"Company Option\"), whether or not vested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Merger Consideration over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger.  At the effective time of the Merger, each Company Option that is then outstanding and unexercised, whether or not vested and which has a per share exercise price that is equal to or greater than the Merger Consideration, shall be cancelled with no consideration payable therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, each unexercised and outstanding option to purchase shares of Common Stock (a \"Company Option\"), whether or not vested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Merger Consideration over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger.  At the effective time of the Merger, each Company Option that is then outstanding and unexercised, whether or not vested and which has a per share exercise price that is equal to or greater than the Merger Consideration, shall be cancelled with no consideration payable therefor."}],"balance_after":0,"derivative":{"exercise_price":7.54,"expiration_date":"2035-03-20","underlying":"Common Stock","underlying_shares":31000},"source":{"system":"sec-edgar","filing":"0001814653-26-000003","document":"form4-08272026_080806.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1419041/000181465326000003/form4-08272026_080806.xml","form_type":"4"}},{"id":673728,"issuer":{"id":9529,"kind":"organization","name":"Forte Biosciences, Inc."},"owners":[{"id":19063,"kind":"person","name":"Kornfeld Steven","position":1,"cik":"0001814653","reported_name":"Kornfeld Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-08-27T20:36:10.000Z","date":"2026-08-27","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":2000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, each unexercised and outstanding option to purchase shares of Common Stock (a \"Company Option\"), whether or not vested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Merger Consideration over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger.  At the effective time of the Merger, each Company Option that is then outstanding and unexercised, whether or not vested and which has a per share exercise price that is equal to or greater than the Merger Consideration, shall be cancelled with no consideration payable therefor."}],"balance_after":0,"derivative":{"exercise_price":8.6,"exercise_date":"2025-05-29","expiration_date":"2034-08-20","underlying":"Common Stock","underlying_shares":2000},"source":{"system":"sec-edgar","filing":"0001814653-26-000003","document":"form4-08272026_080806.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1419041/000181465326000003/form4-08272026_080806.xml","form_type":"4"}},{"id":673727,"issuer":{"id":9529,"kind":"organization","name":"Forte Biosciences, Inc."},"owners":[{"id":19063,"kind":"person","name":"Kornfeld Steven","position":1,"cik":"0001814653","reported_name":"Kornfeld Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-08-27T20:36:10.000Z","date":"2026-08-27","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, each unexercised and outstanding option to purchase shares of Common Stock (a \"Company Option\"), whether or not vested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Merger Consideration over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger.  At the effective time of the Merger, each Company Option that is then outstanding and unexercised, whether or not vested and which has a per share exercise price that is equal to or greater than the Merger Consideration, shall be cancelled with no consideration payable therefor."}],"balance_after":0,"derivative":{"exercise_price":20,"exercise_date":"2024-08-20","expiration_date":"2033-09-19","underlying":"Common Stock","underlying_shares":1000},"source":{"system":"sec-edgar","filing":"0001814653-26-000003","document":"form4-08272026_080806.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1419041/000181465326000003/form4-08272026_080806.xml","form_type":"4"}},{"id":673726,"issuer":{"id":9529,"kind":"organization","name":"Forte Biosciences, Inc."},"owners":[{"id":19063,"kind":"person","name":"Kornfeld Steven","position":1,"cik":"0001814653","reported_name":"Kornfeld Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-08-27T20:36:10.000Z","date":"2026-08-27","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, each unexercised and outstanding option to purchase shares of Common Stock (a \"Company Option\"), whether or not vested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Merger Consideration over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger.  At the effective time of the Merger, each Company Option that is then outstanding and unexercised, whether or not vested and which has a per share exercise price that is equal to or greater than the Merger Consideration, shall be cancelled with no consideration payable therefor."}],"balance_after":0,"derivative":{"exercise_price":31.75,"exercise_date":"2023-06-01","expiration_date":"2032-06-01","underlying":"Common Stock","underlying_shares":1000},"source":{"system":"sec-edgar","filing":"0001814653-26-000003","document":"form4-08272026_080806.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1419041/000181465326000003/form4-08272026_080806.xml","form_type":"4"}},{"id":673725,"issuer":{"id":9529,"kind":"organization","name":"Forte Biosciences, Inc."},"owners":[{"id":19063,"kind":"person","name":"Kornfeld Steven","position":1,"cik":"0001814653","reported_name":"Kornfeld Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-08-27T20:36:10.000Z","date":"2026-08-27","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, each unexercised and outstanding option to purchase shares of Common Stock (a \"Company Option\"), whether or not vested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Merger Consideration over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger.  At the effective time of the Merger, each Company Option that is then outstanding and unexercised, whether or not vested and which has a per share exercise price that is equal to or greater than the Merger Consideration, shall be cancelled with no consideration payable therefor."}],"balance_after":0,"derivative":{"exercise_price":31.75,"exercise_date":"2023-02-23","expiration_date":"2032-02-23","underlying":"Common Stock","underlying_shares":1000},"source":{"system":"sec-edgar","filing":"0001814653-26-000003","document":"form4-08272026_080806.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1419041/000181465326000003/form4-08272026_080806.xml","form_type":"4"}},{"id":673724,"issuer":{"id":9529,"kind":"organization","name":"Forte Biosciences, Inc."},"owners":[{"id":19063,"kind":"person","name":"Kornfeld Steven","position":1,"cik":"0001814653","reported_name":"Kornfeld Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-08-27T20:36:10.000Z","date":"2026-08-27","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":800,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, each unexercised and outstanding option to purchase shares of Common Stock (a \"Company Option\"), whether or not vested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Merger Consideration over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger.  At the effective time of the Merger, each Company Option that is then outstanding and unexercised, whether or not vested and which has a per share exercise price that is equal to or greater than the Merger Consideration, shall be cancelled with no consideration payable therefor."}],"balance_after":0,"derivative":{"exercise_price":888.5,"exercise_date":"2022-05-28","expiration_date":"2031-05-28","underlying":"Common Stock","underlying_shares":800},"source":{"system":"sec-edgar","filing":"0001814653-26-000003","document":"form4-08272026_080806.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1419041/000181465326000003/form4-08272026_080806.xml","form_type":"4"}},{"id":673723,"issuer":{"id":9529,"kind":"organization","name":"Forte Biosciences, Inc."},"owners":[{"id":19063,"kind":"person","name":"Kornfeld Steven","position":1,"cik":"0001814653","reported_name":"Kornfeld Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-08-27T20:36:10.000Z","date":"2026-08-27","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1200,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, each unexercised and outstanding option to purchase shares of Common Stock (a \"Company Option\"), whether or not vested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Merger Consideration over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger.  At the effective time of the Merger, each Company Option that is then outstanding and unexercised, whether or not vested and which has a per share exercise price that is equal to or greater than the Merger Consideration, shall be cancelled with no consideration payable therefor."}],"balance_after":0,"derivative":{"exercise_price":472.5,"exercise_date":"2023-06-15","expiration_date":"2030-06-15","underlying":"Common Stock","underlying_shares":1200},"source":{"system":"sec-edgar","filing":"0001814653-26-000003","document":"form4-08272026_080806.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1419041/000181465326000003/form4-08272026_080806.xml","form_type":"4"}},{"id":673722,"issuer":{"id":9529,"kind":"organization","name":"Forte Biosciences, Inc."},"owners":[{"id":19063,"kind":"person","name":"Kornfeld Steven","position":1,"cik":"0001814653","reported_name":"Kornfeld Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-27T20:36:10.000Z","date":"2026-08-27","kind":"other","planned":false,"acquired":false,"shares":3960,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated July 26, 2026 (the \"Merger Agreement\"), by and among Forte Biosciences, Inc. (\"Company\"), argenx BV (\"Parent\"), and Avena Merger Sub Inc., a wholly owned subsidiary of Parent (\"Purchaser\"), the shares of common stock of Company that were tendered to Purchaser prior to the expiration time of the offer were exchanged for $77.00 per share (\"Merger Consideration\"), net to the seller in cash, without interest, subject to any required withholding tax. After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into Company (the \"Merger\"), with Company surviving the Merger as a wholly owned subsidiary of Parent."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001814653-26-000003","document":"form4-08272026_080806.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1419041/000181465326000003/form4-08272026_080806.xml","form_type":"4"}},{"id":673932,"issuer":{"id":9529,"kind":"organization","name":"Forte Biosciences, Inc."},"owners":[{"id":19110,"kind":"person","name":"Brun Scott C.","position":1,"cik":"0001863614","reported_name":"Brun Scott C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2026-08-27T20:34:59.000Z","date":"2026-08-27","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":18353,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Forte Biosciences, Inc. (the \"Issuer\") Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, each outstanding restricted stock unit (a \"Company RSU\"), whether or not vested, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the Merger Consideration, multiplied by (y) the total number of shares subject to such Company RSU immediately prior to the effective time of the Merger."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, each outstanding restricted stock unit (a \"Company RSU\"), whether or not vested, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the Merger Consideration, multiplied by (y) the total number of shares subject to such Company RSU immediately prior to the effective time of the Merger."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the Merger Agreement, each outstanding restricted stock unit (a \"Company RSU\"), whether or not vested, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the Merger Consideration, multiplied by (y) the total number of shares subject to such Company RSU immediately prior to the effective time of the Merger."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":18353},"source":{"system":"sec-edgar","filing":"0001863614-26-000003","document":"form4-08272026_080854.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1863614/000186361426000003/form4-08272026_080854.xml","form_type":"4"}},{"id":673931,"issuer":{"id":9529,"kind":"organization","name":"Forte Biosciences, Inc."},"owners":[{"id":19110,"kind":"person","name":"Brun Scott C.","position":1,"cik":"0001863614","reported_name":"Brun Scott C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-08-27T20:34:59.000Z","date":"2026-08-27","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":31000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated July 26, 2026 (the \"Merger Agreement\"), by and among Forte Biosciences, Inc. (\"Company\"), argenx BV (\"Parent\"), and Avena Merger Sub Inc., a wholly owned subsidiary of Parent (\"Purchaser\"), each unexercised and outstanding option to purchase shares of Common Stock (a \"Company Option\"), whether or not vested, and which had a per share exercise price that was less than $77.00 per share (\"Merger Consideration\"), was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Merger Consideration over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to Purchaser merging with and into Company (the \"Merger\"), with Company surviving the Merger as a wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"At the effective time of the Merger, each Company Option that is then outstanding and unexercised, whether or not vested and which has a per share exercise price that is equal to or greater than the Merger Consideration, shall be cancelled with no consideration payable therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated July 26, 2026 (the \"Merger Agreement\"), by and among Forte Biosciences, Inc. (\"Company\"), argenx BV (\"Parent\"), and Avena Merger Sub Inc., a wholly owned subsidiary of Parent (\"Purchaser\"), each unexercised and outstanding option to purchase shares of Common Stock (a \"Company Option\"), whether or not vested, and which had a per share exercise price that was less than $77.00 per share (\"Merger Consideration\"), was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Merger Consideration over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to Purchaser merging with and into Company (the \"Merger\"), with Company surviving the Merger as a wholly owned subsidiary of Parent."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"At the effective time of the Merger, each Company Option that is then outstanding and unexercised, whether or not vested and which has a per share exercise price that is equal to or greater than the Merger Consideration, shall be cancelled with no consideration payable therefor."}],"balance_after":0,"derivative":{"exercise_price":7.54,"expiration_date":"2035-03-20","underlying":"Common Stock","underlying_shares":31000},"source":{"system":"sec-edgar","filing":"0001863614-26-000003","document":"form4-08272026_080854.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1863614/000186361426000003/form4-08272026_080854.xml","form_type":"4"}},{"id":673930,"issuer":{"id":9529,"kind":"organization","name":"Forte Biosciences, Inc."},"owners":[{"id":19110,"kind":"person","name":"Brun Scott C.","position":1,"cik":"0001863614","reported_name":"Brun Scott C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-08-27T20:34:59.000Z","date":"2026-08-27","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":2000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated July 26, 2026 (the \"Merger Agreement\"), by and among Forte Biosciences, Inc. (\"Company\"), argenx BV (\"Parent\"), and Avena Merger Sub Inc., a wholly owned subsidiary of Parent (\"Purchaser\"), each unexercised and outstanding option to purchase shares of Common Stock (a \"Company Option\"), whether or not vested, and which had a per share exercise price that was less than $77.00 per share (\"Merger Consideration\"), was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Merger Consideration over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to Purchaser merging with and into Company (the \"Merger\"), with Company surviving the Merger as a wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"At the effective time of the Merger, each Company Option that is then outstanding and unexercised, whether or not vested and which has a per share exercise price that is equal to or greater than the Merger Consideration, shall be cancelled with no consideration payable therefor."}],"balance_after":0,"derivative":{"exercise_price":8.6,"exercise_date":"2025-05-29","expiration_date":"2034-08-20","underlying":"Common Stock","underlying_shares":2000},"source":{"system":"sec-edgar","filing":"0001863614-26-000003","document":"form4-08272026_080854.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1863614/000186361426000003/form4-08272026_080854.xml","form_type":"4"}},{"id":673929,"issuer":{"id":9529,"kind":"organization","name":"Forte Biosciences, Inc."},"owners":[{"id":19110,"kind":"person","name":"Brun Scott C.","position":1,"cik":"0001863614","reported_name":"Brun Scott C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-08-27T20:34:59.000Z","date":"2026-08-27","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated July 26, 2026 (the \"Merger Agreement\"), by and among Forte Biosciences, Inc. (\"Company\"), argenx BV (\"Parent\"), and Avena Merger Sub Inc., a wholly owned subsidiary of Parent (\"Purchaser\"), each unexercised and outstanding option to purchase shares of Common Stock (a \"Company Option\"), whether or not vested, and which had a per share exercise price that was less than $77.00 per share (\"Merger Consideration\"), was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Merger Consideration over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to Purchaser merging with and into Company (the \"Merger\"), with Company surviving the Merger as a wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"At the effective time of the Merger, each Company Option that is then outstanding and unexercised, whether or not vested and which has a per share exercise price that is equal to or greater than the Merger Consideration, shall be cancelled with no consideration payable therefor."}],"balance_after":0,"derivative":{"exercise_price":20,"exercise_date":"2024-08-20","expiration_date":"2033-09-19","underlying":"Common Stock","underlying_shares":1000},"source":{"system":"sec-edgar","filing":"0001863614-26-000003","document":"form4-08272026_080854.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1863614/000186361426000003/form4-08272026_080854.xml","form_type":"4"}},{"id":673928,"issuer":{"id":9529,"kind":"organization","name":"Forte Biosciences, Inc."},"owners":[{"id":19110,"kind":"person","name":"Brun Scott C.","position":1,"cik":"0001863614","reported_name":"Brun Scott C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-08-27T20:34:59.000Z","date":"2026-08-27","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":2000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated July 26, 2026 (the \"Merger Agreement\"), by and among Forte Biosciences, Inc. (\"Company\"), argenx BV (\"Parent\"), and Avena Merger Sub Inc., a wholly owned subsidiary of Parent (\"Purchaser\"), each unexercised and outstanding option to purchase shares of Common Stock (a \"Company Option\"), whether or not vested, and which had a per share exercise price that was less than $77.00 per share (\"Merger Consideration\"), was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Merger Consideration over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to Purchaser merging with and into Company (the \"Merger\"), with Company surviving the Merger as a wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"At the effective time of the Merger, each Company Option that is then outstanding and unexercised, whether or not vested and which has a per share exercise price that is equal to or greater than the Merger Consideration, shall be cancelled with no consideration payable therefor."}],"balance_after":0,"derivative":{"exercise_price":25,"exercise_date":"2025-11-10","expiration_date":"2032-11-10","underlying":"Common Stock","underlying_shares":2000},"source":{"system":"sec-edgar","filing":"0001863614-26-000003","document":"form4-08272026_080854.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863614/000186361426000003/form4-08272026_080854.xml","form_type":"4"}},{"id":673721,"issuer":{"id":9529,"kind":"organization","name":"Forte Biosciences, Inc."},"owners":[{"id":19062,"kind":"person","name":"GRYSKA DAVID W","position":1,"cik":"0001202335","reported_name":"GRYSKA DAVID W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2026-08-27T20:33:05.000Z","date":"2026-08-27","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":18353,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Forte Biosciences, Inc. (the \"Issuer\") Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, each outstanding restricted stock unit (a \"Company RSU\"), whether or not vested, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the Merger Consideration, multiplied by (y) the total number of shares subject to such Company RSU immediately prior to the effective time of the Merger."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, each outstanding restricted stock unit (a \"Company RSU\"), whether or not vested, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the Merger Consideration, multiplied by (y) the total number of shares subject to such Company RSU immediately prior to the effective time of the Merger."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the Merger Agreement, each outstanding restricted stock unit (a \"Company RSU\"), whether or not vested, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the Merger Consideration, multiplied by (y) the total number of shares subject to such Company RSU immediately prior to the effective time of the Merger."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":18353},"source":{"system":"sec-edgar","filing":"0001202335-26-000003","document":"form4-08272026_080800.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1419041/000120233526000003/form4-08272026_080800.xml","form_type":"4"}},{"id":673720,"issuer":{"id":9529,"kind":"organization","name":"Forte Biosciences, Inc."},"owners":[{"id":19062,"kind":"person","name":"GRYSKA DAVID W","position":1,"cik":"0001202335","reported_name":"GRYSKA DAVID W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-08-27T20:33:05.000Z","date":"2026-08-27","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":31000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, each unexercised and outstanding option to purchase shares of Common Stock (a \"Company Option\"), whether or not vested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Merger Consideration over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger.  At the effective time of the Merger, each Company Option that is then outstanding and unexercised, whether or not vested and which has a per share exercise price that is equal to or greater than the Merger Consideration, shall be cancelled with no consideration payable therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, each unexercised and outstanding option to purchase shares of Common Stock (a \"Company Option\"), whether or not vested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Merger Consideration over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger.  At the effective time of the Merger, each Company Option that is then outstanding and unexercised, whether or not vested and which has a per share exercise price that is equal to or greater than the Merger Consideration, shall be cancelled with no consideration payable therefor."}],"balance_after":0,"derivative":{"exercise_price":7.54,"expiration_date":"2035-03-20","underlying":"Common Stock","underlying_shares":31000},"source":{"system":"sec-edgar","filing":"0001202335-26-000003","document":"form4-08272026_080800.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1419041/000120233526000003/form4-08272026_080800.xml","form_type":"4"}},{"id":673719,"issuer":{"id":9529,"kind":"organization","name":"Forte Biosciences, Inc."},"owners":[{"id":19062,"kind":"person","name":"GRYSKA DAVID W","position":1,"cik":"0001202335","reported_name":"GRYSKA DAVID W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)]","published_at":"2026-08-27T20:33:05.000Z","date":"2026-08-27","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":2000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, each unexercised and outstanding option to purchase shares of Common Stock (a \"Company Option\"), whether or not vested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Merger Consideration over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger.  At the effective time of the Merger, each Company Option that is then outstanding and unexercised, whether or not vested and which has a per share exercise price that is equal to or greater than the Merger Consideration, shall be cancelled with no consideration payable therefor."}],"balance_after":0,"derivative":{"exercise_price":8.6,"exercise_date":"2025-05-29","expiration_date":"2034-08-20","underlying":"Common Stock","underlying_shares":2000},"source":{"system":"sec-edgar","filing":"0001202335-26-000003","document":"form4-08272026_080800.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1419041/000120233526000003/form4-08272026_080800.xml","form_type":"4"}},{"id":673718,"issuer":{"id":9529,"kind":"organization","name":"Forte Biosciences, Inc."},"owners":[{"id":19062,"kind":"person","name":"GRYSKA DAVID W","position":1,"cik":"0001202335","reported_name":"GRYSKA DAVID W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-08-27T20:33:05.000Z","date":"2026-08-27","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, each unexercised and outstanding option to purchase shares of Common Stock (a \"Company Option\"), whether or not vested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Merger Consideration over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger.  At the effective time of the Merger, each Company Option that is then outstanding and unexercised, whether or not vested and which has a per share exercise price that is equal to or greater than the Merger Consideration, shall be cancelled with no consideration payable therefor."}],"balance_after":0,"derivative":{"exercise_price":20,"exercise_date":"2024-08-20","expiration_date":"2033-09-19","underlying":"Common Stock","underlying_shares":1000},"source":{"system":"sec-edgar","filing":"0001202335-26-000003","document":"form4-08272026_080800.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1419041/000120233526000003/form4-08272026_080800.xml","form_type":"4"}},{"id":673717,"issuer":{"id":9529,"kind":"organization","name":"Forte Biosciences, Inc."},"owners":[{"id":19062,"kind":"person","name":"GRYSKA DAVID W","position":1,"cik":"0001202335","reported_name":"GRYSKA DAVID W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-08-27T20:33:05.000Z","date":"2026-08-27","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":2000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, each unexercised and outstanding option to purchase shares of Common Stock (a \"Company Option\"), whether or not vested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Merger Consideration over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger.  At the effective time of the Merger, each Company Option that is then outstanding and unexercised, whether or not vested and which has a per share exercise price that is equal to or greater than the Merger Consideration, shall be cancelled with no consideration payable therefor."}],"balance_after":0,"derivative":{"exercise_price":25.5,"exercise_date":"2026-01-10","expiration_date":"2033-01-10","underlying":"Common Stock","underlying_shares":2000},"source":{"system":"sec-edgar","filing":"0001202335-26-000003","document":"form4-08272026_080800.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1419041/000120233526000003/form4-08272026_080800.xml","form_type":"4"}},{"id":673716,"issuer":{"id":9529,"kind":"organization","name":"Forte Biosciences, Inc."},"owners":[{"id":19062,"kind":"person","name":"GRYSKA DAVID W","position":1,"cik":"0001202335","reported_name":"GRYSKA DAVID W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-27T20:33:05.000Z","date":"2026-08-27","kind":"other","planned":false,"acquired":false,"shares":5940,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated July 26, 2026 (the \"Merger Agreement\"), by and among Forte Biosciences, Inc. (\"Company\"), argenx BV (\"Parent\"), and Avena Merger Sub Inc., a wholly owned subsidiary of Parent (\"Purchaser\"), the shares of common stock of Company that were tendered to Purchaser prior to the expiration time of the offer were exchanged for $77.00 per share (\"Merger Consideration\"), net to the seller in cash, without interest, subject to any required withholding tax. After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into Company (the \"Merger\"), with Company surviving the Merger as a wholly owned subsidiary of Parent."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001202335-26-000003","document":"form4-08272026_080800.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1419041/000120233526000003/form4-08272026_080800.xml","form_type":"4"}},{"id":673715,"issuer":{"id":9529,"kind":"organization","name":"Forte Biosciences, Inc."},"owners":[{"id":19061,"kind":"person","name":"VINCENT RICHARD G","position":1,"cik":"0001269341","reported_name":"VINCENT RICHARD G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2026-08-27T20:32:25.000Z","date":"2026-08-27","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":18353,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Forte Biosciences, Inc. (the \"Issuer\") Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, each outstanding restricted stock unit (a \"Company RSU\"), whether or not vested, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the Merger Consideration, multiplied by (y) the total number of shares subject to such Company RSU immediately prior to the effective time of the Merger."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, each outstanding restricted stock unit (a \"Company RSU\"), whether or not vested, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the Merger Consideration, multiplied by (y) the total number of shares subject to such Company RSU immediately prior to the effective time of the Merger."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the Merger Agreement, each outstanding restricted stock unit (a \"Company RSU\"), whether or not vested, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the Merger Consideration, multiplied by (y) the total number of shares subject to such Company RSU immediately prior to the effective time of the Merger."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":18353},"source":{"system":"sec-edgar","filing":"0001269341-26-000003","document":"form4-08272026_080820.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1419041/000126934126000003/form4-08272026_080820.xml","form_type":"4"}},{"id":673714,"issuer":{"id":9529,"kind":"organization","name":"Forte Biosciences, Inc."},"owners":[{"id":19061,"kind":"person","name":"VINCENT RICHARD G","position":1,"cik":"0001269341","reported_name":"VINCENT RICHARD G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-08-27T20:32:25.000Z","date":"2026-08-27","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":31000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated July 26, 2026 (the \"Merger Agreement\"), by and among Forte Biosciences, Inc. (\"Company\"), argenx BV (\"Parent\"), and Avena Merger Sub Inc., a wholly owned subsidiary of Parent (\"Purchaser\"), each unexercised and outstanding option to purchase shares of Common Stock (a \"Company Option\"), whether or not vested, and which had a per share exercise price that was less than $77.00 per share (\"Merger Consideration\"), was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Merger Consideration over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to Purchaser merging with and into Company (the \"Merger\"), with Company surviving the Merger as a wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"At the effective time of the Merger, each Company Option that is then outstanding and unexercised, whether or not vested and which has a per share exercise price that is equal to or greater than the Merger Consideration, shall be cancelled with no consideration payable therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated July 26, 2026 (the \"Merger Agreement\"), by and among Forte Biosciences, Inc. (\"Company\"), argenx BV (\"Parent\"), and Avena Merger Sub Inc., a wholly owned subsidiary of Parent (\"Purchaser\"), each unexercised and outstanding option to purchase shares of Common Stock (a \"Company Option\"), whether or not vested, and which had a per share exercise price that was less than $77.00 per share (\"Merger Consideration\"), was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Merger Consideration over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to Purchaser merging with and into Company (the \"Merger\"), with Company surviving the Merger as a wholly owned subsidiary of Parent."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"At the effective time of the Merger, each Company Option that is then outstanding and unexercised, whether or not vested and which has a per share exercise price that is equal to or greater than the Merger Consideration, shall be cancelled with no consideration payable therefor."}],"balance_after":0,"derivative":{"exercise_price":7.54,"expiration_date":"2035-03-20","underlying":"Common Stock","underlying_shares":31000},"source":{"system":"sec-edgar","filing":"0001269341-26-000003","document":"form4-08272026_080820.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1419041/000126934126000003/form4-08272026_080820.xml","form_type":"4"}},{"id":673713,"issuer":{"id":9529,"kind":"organization","name":"Forte Biosciences, Inc."},"owners":[{"id":19061,"kind":"person","name":"VINCENT RICHARD G","position":1,"cik":"0001269341","reported_name":"VINCENT RICHARD G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-08-27T20:32:25.000Z","date":"2026-08-27","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":2000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated July 26, 2026 (the \"Merger Agreement\"), by and among Forte Biosciences, Inc. (\"Company\"), argenx BV (\"Parent\"), and Avena Merger Sub Inc., a wholly owned subsidiary of Parent (\"Purchaser\"), each unexercised and outstanding option to purchase shares of Common Stock (a \"Company Option\"), whether or not vested, and which had a per share exercise price that was less than $77.00 per share (\"Merger Consideration\"), was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Merger Consideration over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to Purchaser merging with and into Company (the \"Merger\"), with Company surviving the Merger as a wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"At the effective time of the Merger, each Company Option that is then outstanding and unexercised, whether or not vested and which has a per share exercise price that is equal to or greater than the Merger Consideration, shall be cancelled with no consideration payable therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated July 26, 2026 (the \"Merger Agreement\"), by and among Forte Biosciences, Inc. (\"Company\"), argenx BV (\"Parent\"), and Avena Merger Sub Inc., a wholly owned subsidiary of Parent (\"Purchaser\"), each unexercised and outstanding option to purchase shares of Common Stock (a \"Company Option\"), whether or not vested, and which had a per share exercise price that was less than $77.00 per share (\"Merger Consideration\"), was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Merger Consideration over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to Purchaser merging with and into Company (the \"Merger\"), with Company surviving the Merger as a wholly owned subsidiary of Parent."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"At the effective time of the Merger, each Company Option that is then outstanding and unexercised, whether or not vested and which has a per share exercise price that is equal to or greater than the Merger Consideration, shall be cancelled with no consideration payable therefor."}],"balance_after":0,"derivative":{"exercise_price":7.07,"expiration_date":"2034-09-17","underlying":"Common Stock","underlying_shares":2000},"source":{"system":"sec-edgar","filing":"0001269341-26-000003","document":"form4-08272026_080820.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1419041/000126934126000003/form4-08272026_080820.xml","form_type":"4"}},{"id":673712,"issuer":{"id":9529,"kind":"organization","name":"Forte Biosciences, Inc."},"owners":[{"id":19060,"kind":"person","name":"FINCK BARBARA K","position":1,"cik":"0001242116","reported_name":"FINCK BARBARA K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2026-08-27T20:31:40.000Z","date":"2026-08-27","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":18353,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Forte Biosciences, Inc. (the \"Issuer\") Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, each outstanding restricted stock unit (a \"Company RSU\"), whether or not vested, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the Merger Consideration, multiplied by (y) the total number of shares subject to such Company RSU immediately prior to the effective time of the Merger."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, each outstanding restricted stock unit (a \"Company RSU\"), whether or not vested, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the Merger Consideration, multiplied by (y) the total number of shares subject to such Company RSU immediately prior to the effective time of the Merger."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the Merger Agreement, each outstanding restricted stock unit (a \"Company RSU\"), whether or not vested, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the Merger Consideration, multiplied by (y) the total number of shares subject to such Company RSU immediately prior to the effective time of the Merger."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":18353},"source":{"system":"sec-edgar","filing":"0001242116-26-000001","document":"form4-08272026_080835.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1419041/000124211626000001/form4-08272026_080835.xml","form_type":"4"}},{"id":673711,"issuer":{"id":9529,"kind":"organization","name":"Forte Biosciences, Inc."},"owners":[{"id":19060,"kind":"person","name":"FINCK BARBARA K","position":1,"cik":"0001242116","reported_name":"FINCK BARBARA K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-08-27T20:31:40.000Z","date":"2026-08-27","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":31000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated July 26, 2026 (the \"Merger Agreement\"), by and among Forte Biosciences, Inc. (\"Company\"), argenx BV (\"Parent\"), and Avena Merger Sub Inc., a wholly owned subsidiary of Parent (\"Purchaser\"), each unexercised and outstanding option to purchase shares of Common Stock (a \"Company Option\"), whether or not vested, and which had a per share exercise price that was less than $77.00 per share (\"Merger Consideration\"), was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Merger Consideration over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to Purchaser merging with and into Company (the \"Merger\"), with Company surviving the Merger as a wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"At the effective time of the Merger, each Company Option that is then outstanding and unexercised, whether or not vested and which has a per share exercise price that is equal to or greater than the Merger Consideration, shall be cancelled with no consideration payable therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated July 26, 2026 (the \"Merger Agreement\"), by and among Forte Biosciences, Inc. (\"Company\"), argenx BV (\"Parent\"), and Avena Merger Sub Inc., a wholly owned subsidiary of Parent (\"Purchaser\"), each unexercised and outstanding option to purchase shares of Common Stock (a \"Company Option\"), whether or not vested, and which had a per share exercise price that was less than $77.00 per share (\"Merger Consideration\"), was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Merger Consideration over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to Purchaser merging with and into Company (the \"Merger\"), with Company surviving the Merger as a wholly owned subsidiary of Parent."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"At the effective time of the Merger, each Company Option that is then outstanding and unexercised, whether or not vested and which has a per share exercise price that is equal to or greater than the Merger Consideration, shall be cancelled with no consideration payable therefor."}],"balance_after":0,"derivative":{"exercise_price":7.02,"expiration_date":"2035-03-19","underlying":"Common Stock","underlying_shares":31000},"source":{"system":"sec-edgar","filing":"0001242116-26-000001","document":"form4-08272026_080835.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1419041/000124211626000001/form4-08272026_080835.xml","form_type":"4"}},{"id":673710,"issuer":{"id":9529,"kind":"organization","name":"Forte Biosciences, Inc."},"owners":[{"id":19060,"kind":"person","name":"FINCK BARBARA K","position":1,"cik":"0001242116","reported_name":"FINCK BARBARA K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-08-27T20:31:40.000Z","date":"2026-08-27","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":7000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated July 26, 2026 (the \"Merger Agreement\"), by and among Forte Biosciences, Inc. (\"Company\"), argenx BV (\"Parent\"), and Avena Merger Sub Inc., a wholly owned subsidiary of Parent (\"Purchaser\"), each unexercised and outstanding option to purchase shares of Common Stock (a \"Company Option\"), whether or not vested, and which had a per share exercise price that was less than $77.00 per share (\"Merger Consideration\"), was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Merger Consideration over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to Purchaser merging with and into Company (the \"Merger\"), with Company surviving the Merger as a wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"At the effective time of the Merger, each Company Option that is then outstanding and unexercised, whether or not vested and which has a per share exercise price that is equal to or greater than the Merger Consideration, shall be cancelled with no consideration payable therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated July 26, 2026 (the \"Merger Agreement\"), by and among Forte Biosciences, Inc. (\"Company\"), argenx BV (\"Parent\"), and Avena Merger Sub Inc., a wholly owned subsidiary of Parent (\"Purchaser\"), each unexercised and outstanding option to purchase shares of Common Stock (a \"Company Option\"), whether or not vested, and which had a per share exercise price that was less than $77.00 per share (\"Merger Consideration\"), was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Merger Consideration over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to Purchaser merging with and into Company (the \"Merger\"), with Company surviving the Merger as a wholly owned subsidiary of Parent."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"At the effective time of the Merger, each Company Option that is then outstanding and unexercised, whether or not vested and which has a per share exercise price that is equal to or greater than the Merger Consideration, shall be cancelled with no consideration payable therefor."}],"balance_after":0,"derivative":{"exercise_price":17.25,"expiration_date":"2034-03-21","underlying":"Common Stock","underlying_shares":7000},"source":{"system":"sec-edgar","filing":"0001242116-26-000001","document":"form4-08272026_080835.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1419041/000124211626000001/form4-08272026_080835.xml","form_type":"4"}},{"id":673709,"issuer":{"id":9529,"kind":"organization","name":"Forte Biosciences, Inc."},"owners":[{"id":19060,"kind":"person","name":"FINCK BARBARA K","position":1,"cik":"0001242116","reported_name":"FINCK BARBARA K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-08-27T20:31:40.000Z","date":"2026-08-27","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated July 26, 2026 (the \"Merger Agreement\"), by and among Forte Biosciences, Inc. (\"Company\"), argenx BV (\"Parent\"), and Avena Merger Sub Inc., a wholly owned subsidiary of Parent (\"Purchaser\"), each unexercised and outstanding option to purchase shares of Common Stock (a \"Company Option\"), whether or not vested, and which had a per share exercise price that was less than $77.00 per share (\"Merger Consideration\"), was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Merger Consideration over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to Purchaser merging with and into Company (the \"Merger\"), with Company surviving the Merger as a wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"At the effective time of the Merger, each Company Option that is then outstanding and unexercised, whether or not vested and which has a per share exercise price that is equal to or greater than the Merger Consideration, shall be cancelled with no consideration payable therefor."}],"balance_after":0,"derivative":{"exercise_price":20,"exercise_date":"2024-08-20","expiration_date":"2033-09-19","underlying":"Common Stock","underlying_shares":1000},"source":{"system":"sec-edgar","filing":"0001242116-26-000001","document":"form4-08272026_080835.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1419041/000124211626000001/form4-08272026_080835.xml","form_type":"4"}},{"id":673708,"issuer":{"id":9529,"kind":"organization","name":"Forte Biosciences, Inc."},"owners":[{"id":19060,"kind":"person","name":"FINCK BARBARA K","position":1,"cik":"0001242116","reported_name":"FINCK BARBARA K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-08-27T20:31:40.000Z","date":"2026-08-27","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated July 26, 2026 (the \"Merger Agreement\"), by and among Forte Biosciences, Inc. (\"Company\"), argenx BV (\"Parent\"), and Avena Merger Sub Inc., a wholly owned subsidiary of Parent (\"Purchaser\"), each unexercised and outstanding option to purchase shares of Common Stock (a \"Company Option\"), whether or not vested, and which had a per share exercise price that was less than $77.00 per share (\"Merger Consideration\"), was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Merger Consideration over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to Purchaser merging with and into Company (the \"Merger\"), with Company surviving the Merger as a wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"At the effective time of the Merger, each Company Option that is then outstanding and unexercised, whether or not vested and which has a per share exercise price that is equal to or greater than the Merger Consideration, shall be cancelled with no consideration payable therefor."}],"balance_after":0,"derivative":{"exercise_price":31.75,"exercise_date":"2023-06-01","expiration_date":"2032-06-01","underlying":"Common Stock","underlying_shares":1000},"source":{"system":"sec-edgar","filing":"0001242116-26-000001","document":"form4-08272026_080835.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1419041/000124211626000001/form4-08272026_080835.xml","form_type":"4"}},{"id":673707,"issuer":{"id":9529,"kind":"organization","name":"Forte Biosciences, Inc."},"owners":[{"id":19060,"kind":"person","name":"FINCK BARBARA K","position":1,"cik":"0001242116","reported_name":"FINCK BARBARA K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)]","published_at":"2026-08-27T20:31:40.000Z","date":"2026-08-27","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":166,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated July 26, 2026 (the \"Merger Agreement\"), by and among Forte Biosciences, Inc. (\"Company\"), argenx BV (\"Parent\"), and Avena Merger Sub Inc., a wholly owned subsidiary of Parent (\"Purchaser\"), each unexercised and outstanding option to purchase shares of Common Stock (a \"Company Option\"), whether or not vested, and which had a per share exercise price that was less than $77.00 per share (\"Merger Consideration\"), was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Merger Consideration over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to Purchaser merging with and into Company (the \"Merger\"), with Company surviving the Merger as a wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"At the effective time of the Merger, each Company Option that is then outstanding and unexercised, whether or not vested and which has a per share exercise price that is equal to or greater than the Merger Consideration, shall be cancelled with no consideration payable therefor."}],"balance_after":0,"derivative":{"exercise_price":35.75,"exercise_date":"2023-03-16","expiration_date":"2032-03-16","underlying":"Common Stock","underlying_shares":166},"source":{"system":"sec-edgar","filing":"0001242116-26-000001","document":"form4-08272026_080835.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1419041/000124211626000001/form4-08272026_080835.xml","form_type":"4"}},{"id":673706,"issuer":{"id":9529,"kind":"organization","name":"Forte Biosciences, Inc."},"owners":[{"id":19060,"kind":"person","name":"FINCK BARBARA K","position":1,"cik":"0001242116","reported_name":"FINCK BARBARA K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-08-27T20:31:40.000Z","date":"2026-08-27","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":2000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated July 26, 2026 (the \"Merger Agreement\"), by and among Forte Biosciences, Inc. (\"Company\"), argenx BV (\"Parent\"), and Avena Merger Sub Inc., a wholly owned subsidiary of Parent (\"Purchaser\"), each unexercised and outstanding option to purchase shares of Common Stock (a \"Company Option\"), whether or not vested, and which had a per share exercise price that was less than $77.00 per share (\"Merger Consideration\"), was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Merger Consideration over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to Purchaser merging with and into Company (the \"Merger\"), with Company surviving the Merger as a wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"At the effective time of the Merger, each Company Option that is then outstanding and unexercised, whether or not vested and which has a per share exercise price that is equal to or greater than the Merger Consideration, shall be cancelled with no consideration payable therefor."}],"balance_after":0,"derivative":{"exercise_price":35.75,"exercise_date":"2025-03-16","expiration_date":"2032-03-16","underlying":"Common Stock","underlying_shares":2000},"source":{"system":"sec-edgar","filing":"0001242116-26-000001","document":"form4-08272026_080835.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1419041/000124211626000001/form4-08272026_080835.xml","form_type":"4"}},{"id":673979,"issuer":{"id":9529,"kind":"organization","name":"Forte Biosciences, Inc."},"owners":[{"id":19141,"kind":"person","name":"Kapoor Shivpreet Singh","position":1,"cik":"0002038311","reported_name":"Kapoor Shivpreet Singh","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2026-08-27T20:31:02.000Z","date":"2026-08-27","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":18353,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Forte Biosciences, Inc. (the \"Issuer\") Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, each outstanding restricted stock unit (a \"Company RSU\"), whether or not vested, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the Merger Consideration, multiplied by (y) the total number of shares subject to such Company RSU immediately prior to the effective time of the Merger."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, each outstanding restricted stock unit (a \"Company RSU\"), whether or not vested, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the Merger Consideration, multiplied by (y) the total number of shares subject to such Company RSU immediately prior to the effective time of the Merger."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the Merger Agreement, each outstanding restricted stock unit (a \"Company RSU\"), whether or not vested, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the Merger Consideration, multiplied by (y) the total number of shares subject to such Company RSU immediately prior to the effective time of the Merger."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":18353},"source":{"system":"sec-edgar","filing":"0002038311-26-000003","document":"form4-08272026_080858.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2038311/000203831126000003/form4-08272026_080858.xml","form_type":"4"}},{"id":673978,"issuer":{"id":9529,"kind":"organization","name":"Forte Biosciences, Inc."},"owners":[{"id":19141,"kind":"person","name":"Kapoor Shivpreet Singh","position":1,"cik":"0002038311","reported_name":"Kapoor Shivpreet Singh","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-08-27T20:31:02.000Z","date":"2026-08-27","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":31000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated July 26, 2026 (the \"Merger Agreement\"), by and among Forte Biosciences, Inc. (\"Company\"), argenx BV (\"Parent\"), and Avena Merger Sub Inc., a wholly owned subsidiary of Parent (\"Purchaser\"), each unexercised and outstanding option to purchase shares of Common Stock (a \"Company Option\"), whether or not vested, and which had a per share exercise price that was less than $77.00 per share (\"Merger Consideration\"), was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Merger Consideration over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to Purchaser merging with and into Company (the \"Merger\"), with Company surviving the Merger as a wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"At the effective time of the Merger, each Company Option that is then outstanding and unexercised, whether or not vested and which has a per share exercise price that is equal to or greater than the Merger Consideration, shall be cancelled with no consideration payable therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated July 26, 2026 (the \"Merger Agreement\"), by and among Forte Biosciences, Inc. (\"Company\"), argenx BV (\"Parent\"), and Avena Merger Sub Inc., a wholly owned subsidiary of Parent (\"Purchaser\"), each unexercised and outstanding option to purchase shares of Common Stock (a \"Company Option\"), whether or not vested, and which had a per share exercise price that was less than $77.00 per share (\"Merger Consideration\"), was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Merger Consideration over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to Purchaser merging with and into Company (the \"Merger\"), with Company surviving the Merger as a wholly owned subsidiary of Parent."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"At the effective time of the Merger, each Company Option that is then outstanding and unexercised, whether or not vested and which has a per share exercise price that is equal to or greater than the Merger Consideration, shall be cancelled with no consideration payable therefor."}],"balance_after":0,"derivative":{"exercise_price":7.54,"expiration_date":"2035-03-20","underlying":"Common Stock","underlying_shares":31000},"source":{"system":"sec-edgar","filing":"0002038311-26-000003","document":"form4-08272026_080858.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2038311/000203831126000003/form4-08272026_080858.xml","form_type":"4"}},{"id":673977,"issuer":{"id":9529,"kind":"organization","name":"Forte Biosciences, Inc."},"owners":[{"id":19141,"kind":"person","name":"Kapoor Shivpreet Singh","position":1,"cik":"0002038311","reported_name":"Kapoor Shivpreet Singh","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-08-27T20:31:02.000Z","date":"2026-08-27","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":2000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated July 26, 2026 (the \"Merger Agreement\"), by and among Forte Biosciences, Inc. (\"Company\"), argenx BV (\"Parent\"), and Avena Merger Sub Inc., a wholly owned subsidiary of Parent (\"Purchaser\"), each unexercised and outstanding option to purchase shares of Common Stock (a \"Company Option\"), whether or not vested, and which had a per share exercise price that was less than $77.00 per share (\"Merger Consideration\"), was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Merger Consideration over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to Purchaser merging with and into Company (the \"Merger\"), with Company surviving the Merger as a wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"At the effective time of the Merger, each Company Option that is then outstanding and unexercised, whether or not vested and which has a per share exercise price that is equal to or greater than the Merger Consideration, shall be cancelled with no consideration payable therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated July 26, 2026 (the \"Merger Agreement\"), by and among Forte Biosciences, Inc. (\"Company\"), argenx BV (\"Parent\"), and Avena Merger Sub Inc., a wholly owned subsidiary of Parent (\"Purchaser\"), each unexercised and outstanding option to purchase shares of Common Stock (a \"Company Option\"), whether or not vested, and which had a per share exercise price that was less than $77.00 per share (\"Merger Consideration\"), was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Merger Consideration over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to Purchaser merging with and into Company (the \"Merger\"), with Company surviving the Merger as a wholly owned subsidiary of Parent."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"At the effective time of the Merger, each Company Option that is then outstanding and unexercised, whether or not vested and which has a per share exercise price that is equal to or greater than the Merger Consideration, shall be cancelled with no consideration payable therefor."}],"balance_after":0,"derivative":{"exercise_price":7.07,"expiration_date":"2034-09-17","underlying":"Common Stock","underlying_shares":2000},"source":{"system":"sec-edgar","filing":"0002038311-26-000003","document":"form4-08272026_080858.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2038311/000203831126000003/form4-08272026_080858.xml","form_type":"4"}},{"id":673756,"issuer":{"id":9529,"kind":"organization","name":"Forte Biosciences, Inc."},"owners":[{"id":19076,"kind":"person","name":"Doberstein Stephen K","position":1,"cik":"0001480111","reported_name":"Doberstein Stephen K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2026-08-27T20:30:11.000Z","date":"2026-08-27","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":18353,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Forte Biosciences, Inc. (the \"Issuer\") Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, each outstanding restricted stock unit (a \"Company RSU\"), whether or not vested, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the Merger Consideration, multiplied by (y) the total number of shares subject to such Company RSU immediately prior to the effective time of the Merger."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, each outstanding restricted stock unit (a \"Company RSU\"), whether or not vested, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the Merger Consideration, multiplied by (y) the total number of shares subject to such Company RSU immediately prior to the effective time of the Merger."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the Merger Agreement, each outstanding restricted stock unit (a \"Company RSU\"), whether or not vested, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the Merger Consideration, multiplied by (y) the total number of shares subject to such Company RSU immediately prior to the effective time of the Merger."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":18353},"source":{"system":"sec-edgar","filing":"0001480111-26-000003","document":"form4-08272026_080805.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1480111/000148011126000003/form4-08272026_080805.xml","form_type":"4"}},{"id":673755,"issuer":{"id":9529,"kind":"organization","name":"Forte Biosciences, Inc."},"owners":[{"id":19076,"kind":"person","name":"Doberstein Stephen K","position":1,"cik":"0001480111","reported_name":"Doberstein Stephen K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-08-27T20:30:11.000Z","date":"2026-08-27","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":31000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated July 26, 2026 (the \"Merger Agreement\"), by and among Forte Biosciences, Inc. (\"Company\"), argenx BV (\"Parent\"), and Avena Merger Sub Inc., a wholly owned subsidiary of Parent (\"Purchaser\"), each unexercised and outstanding option to purchase shares of Common Stock (a \"Company Option\"), whether or not vested, and which had a per share exercise price that was less than $77.00 per share (\"Merger Consideration\"), was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Merger Consideration over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to Purchaser merging with and into Company (the \"Merger\"), with Company surviving the Merger as a wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"At the effective time of the Merger, each Company Option that is then outstanding and unexercised, whether or not vested and which has a per share exercise price that is equal to or greater than the Merger Consideration, shall be cancelled with no consideration payable therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated July 26, 2026 (the \"Merger Agreement\"), by and among Forte Biosciences, Inc. (\"Company\"), argenx BV (\"Parent\"), and Avena Merger Sub Inc., a wholly owned subsidiary of Parent (\"Purchaser\"), each unexercised and outstanding option to purchase shares of Common Stock (a \"Company Option\"), whether or not vested, and which had a per share exercise price that was less than $77.00 per share (\"Merger Consideration\"), was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Merger Consideration over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to Purchaser merging with and into Company (the \"Merger\"), with Company surviving the Merger as a wholly owned subsidiary of Parent."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"At the effective time of the Merger, each Company Option that is then outstanding and unexercised, whether or not vested and which has a per share exercise price that is equal to or greater than the Merger Consideration, shall be cancelled with no consideration payable therefor."}],"balance_after":0,"derivative":{"exercise_price":7.54,"expiration_date":"2035-03-20","underlying":"Common Stock","underlying_shares":31000},"source":{"system":"sec-edgar","filing":"0001480111-26-000003","document":"form4-08272026_080805.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1480111/000148011126000003/form4-08272026_080805.xml","form_type":"4"}},{"id":673754,"issuer":{"id":9529,"kind":"organization","name":"Forte Biosciences, Inc."},"owners":[{"id":19076,"kind":"person","name":"Doberstein Stephen K","position":1,"cik":"0001480111","reported_name":"Doberstein Stephen K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-08-27T20:30:11.000Z","date":"2026-08-27","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":2000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated July 26, 2026 (the \"Merger Agreement\"), by and among Forte Biosciences, Inc. (\"Company\"), argenx BV (\"Parent\"), and Avena Merger Sub Inc., a wholly owned subsidiary of Parent (\"Purchaser\"), each unexercised and outstanding option to purchase shares of Common Stock (a \"Company Option\"), whether or not vested, and which had a per share exercise price that was less than $77.00 per share (\"Merger Consideration\"), was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Merger Consideration over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to Purchaser merging with and into Company (the \"Merger\"), with Company surviving the Merger as a wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"At the effective time of the Merger, each Company Option that is then outstanding and unexercised, whether or not vested and which has a per share exercise price that is equal to or greater than the Merger Consideration, shall be cancelled with no consideration payable therefor."}],"balance_after":0,"derivative":{"exercise_price":8.6,"exercise_date":"2025-05-29","expiration_date":"2034-08-20","underlying":"Common Stock","underlying_shares":2000},"source":{"system":"sec-edgar","filing":"0001480111-26-000003","document":"form4-08272026_080805.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1480111/000148011126000003/form4-08272026_080805.xml","form_type":"4"}},{"id":673753,"issuer":{"id":9529,"kind":"organization","name":"Forte Biosciences, Inc."},"owners":[{"id":19076,"kind":"person","name":"Doberstein Stephen K","position":1,"cik":"0001480111","reported_name":"Doberstein Stephen K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-08-27T20:30:11.000Z","date":"2026-08-27","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated July 26, 2026 (the \"Merger Agreement\"), by and among Forte Biosciences, Inc. (\"Company\"), argenx BV (\"Parent\"), and Avena Merger Sub Inc., a wholly owned subsidiary of Parent (\"Purchaser\"), each unexercised and outstanding option to purchase shares of Common Stock (a \"Company Option\"), whether or not vested, and which had a per share exercise price that was less than $77.00 per share (\"Merger Consideration\"), was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Merger Consideration over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to Purchaser merging with and into Company (the \"Merger\"), with Company surviving the Merger as a wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"At the effective time of the Merger, each Company Option that is then outstanding and unexercised, whether or not vested and which has a per share exercise price that is equal to or greater than the Merger Consideration, shall be cancelled with no consideration payable therefor."}],"balance_after":0,"derivative":{"exercise_price":20,"exercise_date":"2024-08-20","expiration_date":"2033-09-19","underlying":"Common Stock","underlying_shares":1000},"source":{"system":"sec-edgar","filing":"0001480111-26-000003","document":"form4-08272026_080805.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1480111/000148011126000003/form4-08272026_080805.xml","form_type":"4"}},{"id":673752,"issuer":{"id":9529,"kind":"organization","name":"Forte Biosciences, Inc."},"owners":[{"id":19076,"kind":"person","name":"Doberstein Stephen K","position":1,"cik":"0001480111","reported_name":"Doberstein Stephen K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-08-27T20:30:11.000Z","date":"2026-08-27","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated July 26, 2026 (the \"Merger Agreement\"), by and among Forte Biosciences, Inc. (\"Company\"), argenx BV (\"Parent\"), and Avena Merger Sub Inc., a wholly owned subsidiary of Parent (\"Purchaser\"), each unexercised and outstanding option to purchase shares of Common Stock (a \"Company Option\"), whether or not vested, and which had a per share exercise price that was less than $77.00 per share (\"Merger Consideration\"), was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Merger Consideration over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to Purchaser merging with and into Company (the \"Merger\"), with Company surviving the Merger as a wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"At the effective time of the Merger, each Company Option that is then outstanding and unexercised, whether or not vested and which has a per share exercise price that is equal to or greater than the Merger Consideration, shall be cancelled with no consideration payable therefor."}],"balance_after":0,"derivative":{"exercise_price":31.75,"exercise_date":"2023-06-01","expiration_date":"2032-06-01","underlying":"Common Stock","underlying_shares":1000},"source":{"system":"sec-edgar","filing":"0001480111-26-000003","document":"form4-08272026_080805.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1480111/000148011126000003/form4-08272026_080805.xml","form_type":"4"}},{"id":673751,"issuer":{"id":9529,"kind":"organization","name":"Forte Biosciences, Inc."},"owners":[{"id":19076,"kind":"person","name":"Doberstein Stephen K","position":1,"cik":"0001480111","reported_name":"Doberstein Stephen K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-08-27T20:30:11.000Z","date":"2026-08-27","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":2000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated July 26, 2026 (the \"Merger Agreement\"), by and among Forte Biosciences, Inc. (\"Company\"), argenx BV (\"Parent\"), and Avena Merger Sub Inc., a wholly owned subsidiary of Parent (\"Purchaser\"), each unexercised and outstanding option to purchase shares of Common Stock (a \"Company Option\"), whether or not vested, and which had a per share exercise price that was less than $77.00 per share (\"Merger Consideration\"), was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Merger Consideration over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to Purchaser merging with and into Company (the \"Merger\"), with Company surviving the Merger as a wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"At the effective time of the Merger, each Company Option that is then outstanding and unexercised, whether or not vested and which has a per share exercise price that is equal to or greater than the Merger Consideration, shall be cancelled with no consideration payable therefor."}],"balance_after":0,"derivative":{"exercise_price":29.5,"exercise_date":"2025-05-12","expiration_date":"2032-05-12","underlying":"Common Stock","underlying_shares":2000},"source":{"system":"sec-edgar","filing":"0001480111-26-000003","document":"form4-08272026_080805.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1480111/000148011126000003/form4-08272026_080805.xml","form_type":"4"}},{"id":673694,"issuer":{"id":9529,"kind":"organization","name":"Forte Biosciences, Inc."},"owners":[{"id":19058,"kind":"person","name":"Riley Antony A","position":1,"cik":"0001339375","reported_name":"Riley Antony A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Restricted Stock Units","published_at":"2026-08-27T20:28:56.000Z","date":"2026-08-27","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":2976,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Forte Biosciences, Inc. Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, each outstanding restricted stock unit (a \"Company RSU\"), whether or not vested, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the Merger Consideration, multiplied by (y) the total number of shares subject to such Company RSU immediately prior to the effective time of the Merger."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, each outstanding restricted stock unit (a \"Company RSU\"), whether or not vested, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the Merger Consideration, multiplied by (y) the total number of shares subject to such Company RSU immediately prior to the effective time of the Merger."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the Merger Agreement, each outstanding restricted stock unit (a \"Company RSU\"), whether or not vested, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the Merger Consideration, multiplied by (y) the total number of shares subject to such Company RSU immediately prior to the effective time of the Merger."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2976},"source":{"system":"sec-edgar","filing":"0001339375-26-000011","document":"form4-08272026_080850.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1419041/000133937526000011/form4-08272026_080850.xml","form_type":"4"}},{"id":673693,"issuer":{"id":9529,"kind":"organization","name":"Forte Biosciences, Inc."},"owners":[{"id":19058,"kind":"person","name":"Riley Antony A","position":1,"cik":"0001339375","reported_name":"Riley Antony A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Restricted Stock Units","published_at":"2026-08-27T20:28:56.000Z","date":"2026-08-27","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":60000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Forte Biosciences, Inc. Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, each outstanding restricted stock unit (a \"Company RSU\"), whether or not vested, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the Merger Consideration, multiplied by (y) the total number of shares subject to such Company RSU immediately prior to the effective time of the Merger."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, each outstanding restricted stock unit (a \"Company RSU\"), whether or not vested, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the Merger Consideration, multiplied by (y) the total number of shares subject to such Company RSU immediately prior to the effective time of the Merger."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the Merger Agreement, each outstanding restricted stock unit (a \"Company RSU\"), whether or not vested, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the Merger Consideration, multiplied by (y) the total number of shares subject to such Company RSU immediately prior to the effective time of the Merger."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001339375-26-000011","document":"form4-08272026_080850.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1419041/000133937526000011/form4-08272026_080850.xml","form_type":"4"}},{"id":673692,"issuer":{"id":9529,"kind":"organization","name":"Forte Biosciences, Inc."},"owners":[{"id":19058,"kind":"person","name":"Riley Antony A","position":1,"cik":"0001339375","reported_name":"Riley Antony A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Restricted Stock Units","published_at":"2026-08-27T20:28:56.000Z","date":"2026-08-27","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":750,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Forte Biosciences, Inc. Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, each outstanding restricted stock unit (a \"Company RSU\"), whether or not vested, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the Merger Consideration, multiplied by (y) the total number of shares subject to such Company RSU immediately prior to the effective time of the Merger."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, each outstanding restricted stock unit (a \"Company RSU\"), whether or not vested, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the Merger Consideration, multiplied by (y) the total number of shares subject to such Company RSU immediately prior to the effective time of the Merger."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the Merger Agreement, each outstanding restricted stock unit (a \"Company RSU\"), whether or not vested, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the Merger Consideration, multiplied by (y) the total number of shares subject to such Company RSU immediately prior to the effective time of the Merger."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":750},"source":{"system":"sec-edgar","filing":"0001339375-26-000011","document":"form4-08272026_080850.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1419041/000133937526000011/form4-08272026_080850.xml","form_type":"4"}},{"id":673691,"issuer":{"id":9529,"kind":"organization","name":"Forte Biosciences, Inc."},"owners":[{"id":19058,"kind":"person","name":"Riley Antony A","position":1,"cik":"0001339375","reported_name":"Riley Antony A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Stock Option (right to buy)","published_at":"2026-08-27T20:28:56.000Z","date":"2026-08-27","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":22000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, each unexercised and outstanding option to purchase shares of Common Stock (a \"Company Option\"), whether or not vested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Merger Consideration over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger.  At the effective time of the Merger, each Company Option that is then outstanding and unexercised, whether or not vested and which has a per share exercise price that is equal to or greater than the Merger Consideration, shall be cancelled with no consideration payable therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, each unexercised and outstanding option to purchase shares of Common Stock (a \"Company Option\"), whether or not vested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Merger Consideration over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger.  At the effective time of the Merger, each Company Option that is then outstanding and unexercised, whether or not vested and which has a per share exercise price that is equal to or greater than the Merger Consideration, shall be cancelled with no consideration payable therefor."}],"balance_after":0,"derivative":{"exercise_price":17.15,"expiration_date":"2036-06-16","underlying":"Common Stock","underlying_shares":22000},"source":{"system":"sec-edgar","filing":"0001339375-26-000011","document":"form4-08272026_080850.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1419041/000133937526000011/form4-08272026_080850.xml","form_type":"4"}},{"id":673690,"issuer":{"id":9529,"kind":"organization","name":"Forte Biosciences, Inc."},"owners":[{"id":19058,"kind":"person","name":"Riley Antony A","position":1,"cik":"0001339375","reported_name":"Riley Antony A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Stock Option (right to buy)","published_at":"2026-08-27T20:28:56.000Z","date":"2026-08-27","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":90000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, each unexercised and outstanding option to purchase shares of Common Stock (a \"Company Option\"), whether or not vested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Merger Consideration over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger.  At the effective time of the Merger, each Company Option that is then outstanding and unexercised, whether or not vested and which has a per share exercise price that is equal to or greater than the Merger Consideration, shall be cancelled with no consideration payable therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, each unexercised and outstanding option to purchase shares of Common Stock (a \"Company Option\"), whether or not vested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Merger Consideration over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger.  At the effective time of the Merger, each Company Option that is then outstanding and unexercised, whether or not vested and which has a per share exercise price that is equal to or greater than the Merger Consideration, shall be cancelled with no consideration payable therefor."}],"balance_after":0,"derivative":{"exercise_price":29.66,"expiration_date":"2036-01-12","underlying":"Common Stock","underlying_shares":90000},"source":{"system":"sec-edgar","filing":"0001339375-26-000011","document":"form4-08272026_080850.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1419041/000133937526000011/form4-08272026_080850.xml","form_type":"4"}},{"id":673689,"issuer":{"id":9529,"kind":"organization","name":"Forte Biosciences, Inc."},"owners":[{"id":19058,"kind":"person","name":"Riley Antony A","position":1,"cik":"0001339375","reported_name":"Riley Antony A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Stock Option (right to buy)","published_at":"2026-08-27T20:28:56.000Z","date":"2026-08-27","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":323000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, each unexercised and outstanding option to purchase shares of Common Stock (a \"Company Option\"), whether or not vested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Merger Consideration over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger.  At the effective time of the Merger, each Company Option that is then outstanding and unexercised, whether or not vested and which has a per share exercise price that is equal to or greater than the Merger Consideration, shall be cancelled with no consideration payable therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, each unexercised and outstanding option to purchase shares of Common Stock (a \"Company Option\"), whether or not vested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Merger Consideration over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger.  At the effective time of the Merger, each Company Option that is then outstanding and unexercised, whether or not vested and which has a per share exercise price that is equal to or greater than the Merger Consideration, shall be cancelled with no consideration payable therefor."}],"balance_after":0,"derivative":{"exercise_price":7.54,"expiration_date":"2035-03-20","underlying":"Common Stock","underlying_shares":323000},"source":{"system":"sec-edgar","filing":"0001339375-26-000011","document":"form4-08272026_080850.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1419041/000133937526000011/form4-08272026_080850.xml","form_type":"4"}},{"id":673688,"issuer":{"id":9529,"kind":"organization","name":"Forte Biosciences, Inc."},"owners":[{"id":19058,"kind":"person","name":"Riley Antony A","position":1,"cik":"0001339375","reported_name":"Riley Antony A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Stock Option (right to buy)","published_at":"2026-08-27T20:28:56.000Z","date":"2026-08-27","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":14000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, each unexercised and outstanding option to purchase shares of Common Stock (a \"Company Option\"), whether or not vested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Merger Consideration over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger.  At the effective time of the Merger, each Company Option that is then outstanding and unexercised, whether or not vested and which has a per share exercise price that is equal to or greater than the Merger Consideration, shall be cancelled with no consideration payable therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, each unexercised and outstanding option to purchase shares of Common Stock (a \"Company Option\"), whether or not vested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Merger Consideration over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger.  At the effective time of the Merger, each Company Option that is then outstanding and unexercised, whether or not vested and which has a per share exercise price that is equal to or greater than the Merger Consideration, shall be cancelled with no consideration payable therefor."}],"balance_after":0,"derivative":{"exercise_price":17.25,"expiration_date":"2034-03-21","underlying":"Common Stock","underlying_shares":14000},"source":{"system":"sec-edgar","filing":"0001339375-26-000011","document":"form4-08272026_080850.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1419041/000133937526000011/form4-08272026_080850.xml","form_type":"4"}},{"id":673687,"issuer":{"id":9529,"kind":"organization","name":"Forte Biosciences, Inc."},"owners":[{"id":19058,"kind":"person","name":"Riley Antony A","position":1,"cik":"0001339375","reported_name":"Riley Antony A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Stock Option (right to buy)","published_at":"2026-08-27T20:28:56.000Z","date":"2026-08-27","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":2999,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, each unexercised and outstanding option to purchase shares of Common Stock (a \"Company Option\"), whether or not vested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Merger Consideration over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger.  At the effective time of the Merger, each Company Option that is then outstanding and unexercised, whether or not vested and which has a per share exercise price that is equal to or greater than the Merger Consideration, shall be cancelled with no consideration payable therefor."}],"balance_after":0,"derivative":{"exercise_price":43,"exercise_date":"2026-01-17","expiration_date":"2032-01-17","underlying":"Common Stock","underlying_shares":2999},"source":{"system":"sec-edgar","filing":"0001339375-26-000011","document":"form4-08272026_080850.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1419041/000133937526000011/form4-08272026_080850.xml","form_type":"4"}},{"id":673686,"issuer":{"id":9529,"kind":"organization","name":"Forte Biosciences, Inc."},"owners":[{"id":19058,"kind":"person","name":"Riley Antony A","position":1,"cik":"0001339375","reported_name":"Riley Antony A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Stock Option (right to buy)","published_at":"2026-08-27T20:28:56.000Z","date":"2026-08-27","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1700,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, each unexercised and outstanding option to purchase shares of Common Stock (a \"Company Option\"), whether or not vested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Merger Consideration over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger.  At the effective time of the Merger, each Company Option that is then outstanding and unexercised, whether or not vested and which has a per share exercise price that is equal to or greater than the Merger Consideration, shall be cancelled with no consideration payable therefor."}],"balance_after":0,"derivative":{"exercise_price":991.5,"exercise_date":"2025-04-09","expiration_date":"2031-04-09","underlying":"Common Stock","underlying_shares":1700},"source":{"system":"sec-edgar","filing":"0001339375-26-000011","document":"form4-08272026_080850.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1419041/000133937526000011/form4-08272026_080850.xml","form_type":"4"}},{"id":673685,"issuer":{"id":9529,"kind":"organization","name":"Forte Biosciences, Inc."},"owners":[{"id":19058,"kind":"person","name":"Riley Antony A","position":1,"cik":"0001339375","reported_name":"Riley Antony A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Stock Option (right to buy)","published_at":"2026-08-27T20:28:56.000Z","date":"2026-08-27","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":2999,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, each unexercised and outstanding option to purchase shares of Common Stock (a \"Company Option\"), whether or not vested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Merger Consideration over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger.  At the effective time of the Merger, each Company Option that is then outstanding and unexercised, whether or not vested and which has a per share exercise price that is equal to or greater than the Merger Consideration, shall be cancelled with no consideration payable therefor."}],"balance_after":0,"derivative":{"exercise_price":364.5,"exercise_date":"2024-03-23","expiration_date":"2030-06-30","underlying":"Common Stock","underlying_shares":2999},"source":{"system":"sec-edgar","filing":"0001339375-26-000011","document":"form4-08272026_080850.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1419041/000133937526000011/form4-08272026_080850.xml","form_type":"4"}},{"id":673684,"issuer":{"id":9529,"kind":"organization","name":"Forte Biosciences, Inc."},"owners":[{"id":19058,"kind":"person","name":"Riley Antony A","position":1,"cik":"0001339375","reported_name":"Riley Antony A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Stock Option (right to buy)","published_at":"2026-08-27T20:28:56.000Z","date":"2026-08-27","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":421,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, each unexercised and outstanding option to purchase shares of Common Stock (a \"Company Option\"), whether or not vested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Merger Consideration over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger.  At the effective time of the Merger, each Company Option that is then outstanding and unexercised, whether or not vested and which has a per share exercise price that is equal to or greater than the Merger Consideration, shall be cancelled with no consideration payable therefor."}],"balance_after":0,"derivative":{"exercise_price":31,"exercise_date":"2024-03-24","expiration_date":"2030-03-29","underlying":"Common Stock","underlying_shares":421},"source":{"system":"sec-edgar","filing":"0001339375-26-000011","document":"form4-08272026_080850.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1419041/000133937526000011/form4-08272026_080850.xml","form_type":"4"}},{"id":673683,"issuer":{"id":9529,"kind":"organization","name":"Forte Biosciences, Inc."},"owners":[{"id":19058,"kind":"person","name":"Riley Antony A","position":1,"cik":"0001339375","reported_name":"Riley Antony A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2026-08-27T20:28:56.000Z","date":"2026-08-27","kind":"other","planned":false,"acquired":false,"shares":42600,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated July 26, 2026 (the \"Merger Agreement\"), by and among Forte Biosciences, Inc. (\"Company\"), argenx BV (\"Parent\"), and Avena Merger Sub Inc., a wholly owned subsidiary of Parent (\"Purchaser\"), the shares of common stock of Company that were tendered to Purchaser prior to the expiration time of the offer were exchanged for $77.00 per share (\"Merger Consideration\"), net to the seller in cash, without interest, subject to any required withholding tax. After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into Company (the \"Merger\"), with Company surviving the Merger as a wholly owned subsidiary of Parent."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001339375-26-000011","document":"form4-08272026_080850.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1419041/000133937526000011/form4-08272026_080850.xml","form_type":"4"}},{"id":673705,"issuer":{"id":9529,"kind":"organization","name":"Forte Biosciences, Inc."},"owners":[{"id":19059,"kind":"person","name":"Wagner Paul A.","position":1,"cik":"0001612842","reported_name":"Wagner Paul A.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SEE REMARKS"}}],"security":"Restricted Stock Units","published_at":"2026-08-27T20:28:06.000Z","date":"2026-08-27","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":3511,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Forte Biosciences, Inc. Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, each outstanding restricted stock unit (a \"Company RSU\"), whether or not vested, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the Merger Consideration, multiplied by (y) the total number of shares subject to such Company RSU immediately prior to the effective time of the Merger."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, each outstanding restricted stock unit (a \"Company RSU\"), whether or not vested, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the Merger Consideration, multiplied by (y) the total number of shares subject to such Company RSU immediately prior to the effective time of the Merger."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the Merger Agreement, each outstanding restricted stock unit (a \"Company RSU\"), whether or not vested, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the Merger Consideration, multiplied by (y) the total number of shares subject to such Company RSU immediately prior to the effective time of the Merger."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3511},"source":{"system":"sec-edgar","filing":"0001612842-26-000011","document":"form4-08272026_080801.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1419041/000161284226000011/form4-08272026_080801.xml","form_type":"4"}},{"id":673704,"issuer":{"id":9529,"kind":"organization","name":"Forte Biosciences, Inc."},"owners":[{"id":19059,"kind":"person","name":"Wagner Paul A.","position":1,"cik":"0001612842","reported_name":"Wagner Paul A.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SEE REMARKS"}}],"security":"Restricted Stock Units","published_at":"2026-08-27T20:28:06.000Z","date":"2026-08-27","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":180000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Forte Biosciences, Inc. Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, each outstanding restricted stock unit (a \"Company RSU\"), whether or not vested, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the Merger Consideration, multiplied by (y) the total number of shares subject to such Company RSU immediately prior to the effective time of the Merger."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, each outstanding restricted stock unit (a \"Company RSU\"), whether or not vested, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the Merger Consideration, multiplied by (y) the total number of shares subject to such Company RSU immediately prior to the effective time of the Merger."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the Merger Agreement, each outstanding restricted stock unit (a \"Company RSU\"), whether or not vested, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the Merger Consideration, multiplied by (y) the total number of shares subject to such Company RSU immediately prior to the effective time of the Merger."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":180000},"source":{"system":"sec-edgar","filing":"0001612842-26-000011","document":"form4-08272026_080801.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1419041/000161284226000011/form4-08272026_080801.xml","form_type":"4"}},{"id":673703,"issuer":{"id":9529,"kind":"organization","name":"Forte Biosciences, Inc."},"owners":[{"id":19059,"kind":"person","name":"Wagner Paul A.","position":1,"cik":"0001612842","reported_name":"Wagner Paul A.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SEE REMARKS"}}],"security":"Restricted Stock Units","published_at":"2026-08-27T20:28:06.000Z","date":"2026-08-27","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":2500,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Forte Biosciences, Inc. Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, each outstanding restricted stock unit (a \"Company RSU\"), whether or not vested, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the Merger Consideration, multiplied by (y) the total number of shares subject to such Company RSU immediately prior to the effective time of the Merger."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, each outstanding restricted stock unit (a \"Company RSU\"), whether or not vested, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the Merger Consideration, multiplied by (y) the total number of shares subject to such Company RSU immediately prior to the effective time of the Merger."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the Merger Agreement, each outstanding restricted stock unit (a \"Company RSU\"), whether or not vested, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the Merger Consideration, multiplied by (y) the total number of shares subject to such Company RSU immediately prior to the effective time of the Merger."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2500},"source":{"system":"sec-edgar","filing":"0001612842-26-000011","document":"form4-08272026_080801.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1419041/000161284226000011/form4-08272026_080801.xml","form_type":"4"}},{"id":673702,"issuer":{"id":9529,"kind":"organization","name":"Forte Biosciences, Inc."},"owners":[{"id":19059,"kind":"person","name":"Wagner Paul A.","position":1,"cik":"0001612842","reported_name":"Wagner Paul A.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SEE REMARKS"}}],"security":"Stock Option (right to buy)","published_at":"2026-08-27T20:28:06.000Z","date":"2026-08-27","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":500000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, each unexercised and outstanding option to purchase shares of Common Stock (a \"Company Option\"), whether or not vested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Merger Consideration over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger.  At the effective time of the Merger, each Company Option that is then outstanding and unexercised, whether or not vested and which has a per share exercise price that is equal to or greater than the Merger Consideration, shall be cancelled with no consideration payable therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, each unexercised and outstanding option to purchase shares of Common Stock (a \"Company Option\"), whether or not vested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Merger Consideration over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger.  At the effective time of the Merger, each Company Option that is then outstanding and unexercised, whether or not vested and which has a per share exercise price that is equal to or greater than the Merger Consideration, shall be cancelled with no consideration payable therefor."}],"balance_after":0,"derivative":{"exercise_price":17.15,"expiration_date":"2036-06-16","underlying":"Common Stock","underlying_shares":500000},"source":{"system":"sec-edgar","filing":"0001612842-26-000011","document":"form4-08272026_080801.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1419041/000161284226000011/form4-08272026_080801.xml","form_type":"4"}},{"id":673701,"issuer":{"id":9529,"kind":"organization","name":"Forte Biosciences, Inc."},"owners":[{"id":19059,"kind":"person","name":"Wagner Paul A.","position":1,"cik":"0001612842","reported_name":"Wagner Paul A.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SEE REMARKS"}}],"security":"Stock Option (right to buy)","published_at":"2026-08-27T20:28:06.000Z","date":"2026-08-27","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":270000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, each unexercised and outstanding option to purchase shares of Common Stock (a \"Company Option\"), whether or not vested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Merger Consideration over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger.  At the effective time of the Merger, each Company Option that is then outstanding and unexercised, whether or not vested and which has a per share exercise price that is equal to or greater than the Merger Consideration, shall be cancelled with no consideration payable therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, each unexercised and outstanding option to purchase shares of Common Stock (a \"Company Option\"), whether or not vested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Merger Consideration over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger.  At the effective time of the Merger, each Company Option that is then outstanding and unexercised, whether or not vested and which has a per share exercise price that is equal to or greater than the Merger Consideration, shall be cancelled with no consideration payable therefor."}],"balance_after":0,"derivative":{"exercise_price":29.66,"expiration_date":"2036-01-12","underlying":"Common Stock","underlying_shares":270000},"source":{"system":"sec-edgar","filing":"0001612842-26-000011","document":"form4-08272026_080801.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1419041/000161284226000011/form4-08272026_080801.xml","form_type":"4"}},{"id":673700,"issuer":{"id":9529,"kind":"organization","name":"Forte Biosciences, Inc."},"owners":[{"id":19059,"kind":"person","name":"Wagner Paul A.","position":1,"cik":"0001612842","reported_name":"Wagner Paul A.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SEE REMARKS"}}],"security":"Stock Option (right to buy)","published_at":"2026-08-27T20:28:06.000Z","date":"2026-08-27","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":920000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, each unexercised and outstanding option to purchase shares of Common Stock (a \"Company Option\"), whether or not vested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Merger Consideration over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger.  At the effective time of the Merger, each Company Option that is then outstanding and unexercised, whether or not vested and which has a per share exercise price that is equal to or greater than the Merger Consideration, shall be cancelled with no consideration payable therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, each unexercised and outstanding option to purchase shares of Common Stock (a \"Company Option\"), whether or not vested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Merger Consideration over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger.  At the effective time of the Merger, each Company Option that is then outstanding and unexercised, whether or not vested and which has a per share exercise price that is equal to or greater than the Merger Consideration, shall be cancelled with no consideration payable therefor."}],"balance_after":0,"derivative":{"exercise_price":7.54,"expiration_date":"2035-03-20","underlying":"Common Stock","underlying_shares":920000},"source":{"system":"sec-edgar","filing":"0001612842-26-000011","document":"form4-08272026_080801.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1419041/000161284226000011/form4-08272026_080801.xml","form_type":"4"}},{"id":673699,"issuer":{"id":9529,"kind":"organization","name":"Forte Biosciences, Inc."},"owners":[{"id":19059,"kind":"person","name":"Wagner Paul A.","position":1,"cik":"0001612842","reported_name":"Wagner Paul A.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SEE REMARKS"}}],"security":"Stock Option (right to buy)","published_at":"2026-08-27T20:28:06.000Z","date":"2026-08-27","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":44000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, each unexercised and outstanding option to purchase shares of Common Stock (a \"Company Option\"), whether or not vested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Merger Consideration over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger.  At the effective time of the Merger, each Company Option that is then outstanding and unexercised, whether or not vested and which has a per share exercise price that is equal to or greater than the Merger Consideration, shall be cancelled with no consideration payable therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, each unexercised and outstanding option to purchase shares of Common Stock (a \"Company Option\"), whether or not vested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Merger Consideration over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger.  At the effective time of the Merger, each Company Option that is then outstanding and unexercised, whether or not vested and which has a per share exercise price that is equal to or greater than the Merger Consideration, shall be cancelled with no consideration payable therefor."}],"balance_after":0,"derivative":{"exercise_price":17.25,"expiration_date":"2034-03-21","underlying":"Common Stock","underlying_shares":44000},"source":{"system":"sec-edgar","filing":"0001612842-26-000011","document":"form4-08272026_080801.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1419041/000161284226000011/form4-08272026_080801.xml","form_type":"4"}},{"id":673698,"issuer":{"id":9529,"kind":"organization","name":"Forte Biosciences, Inc."},"owners":[{"id":19059,"kind":"person","name":"Wagner Paul A.","position":1,"cik":"0001612842","reported_name":"Wagner Paul A.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SEE REMARKS"}}],"security":"Stock Option (right to buy)","published_at":"2026-08-27T20:28:06.000Z","date":"2026-08-27","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":11999,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, each unexercised and outstanding option to purchase shares of Common Stock (a \"Company Option\"), whether or not vested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Merger Consideration over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger.  At the effective time of the Merger, each Company Option that is then outstanding and unexercised, whether or not vested and which has a per share exercise price that is equal to or greater than the Merger Consideration, shall be cancelled with no consideration payable therefor."}],"balance_after":0,"derivative":{"exercise_price":43,"exercise_date":"2026-01-17","expiration_date":"2032-01-17","underlying":"Common Stock","underlying_shares":11999},"source":{"system":"sec-edgar","filing":"0001612842-26-000011","document":"form4-08272026_080801.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1419041/000161284226000011/form4-08272026_080801.xml","form_type":"4"}},{"id":673697,"issuer":{"id":9529,"kind":"organization","name":"Forte Biosciences, Inc."},"owners":[{"id":19059,"kind":"person","name":"Wagner Paul A.","position":1,"cik":"0001612842","reported_name":"Wagner Paul A.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SEE REMARKS"}}],"security":"Stock Option (right to buy)","published_at":"2026-08-27T20:28:06.000Z","date":"2026-08-27","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":5400,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, each unexercised and outstanding option to purchase shares of Common Stock (a \"Company Option\"), whether or not vested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Merger Consideration over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger.  At the effective time of the Merger, each Company Option that is then outstanding and unexercised, whether or not vested and which has a per share exercise price that is equal to or greater than the Merger Consideration, shall be cancelled with no consideration payable therefor."}],"balance_after":0,"derivative":{"exercise_price":991.5,"exercise_date":"2025-04-09","expiration_date":"2031-04-09","underlying":"Common Stock","underlying_shares":5400},"source":{"system":"sec-edgar","filing":"0001612842-26-000011","document":"form4-08272026_080801.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1419041/000161284226000011/form4-08272026_080801.xml","form_type":"4"}},{"id":673696,"issuer":{"id":9529,"kind":"organization","name":"Forte Biosciences, Inc."},"owners":[{"id":19059,"kind":"person","name":"Wagner Paul A.","position":1,"cik":"0001612842","reported_name":"Wagner Paul A.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SEE REMARKS"}}],"security":"Stock Option (right to buy)","published_at":"2026-08-27T20:28:06.000Z","date":"2026-08-27","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":16866,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, each unexercised and outstanding option to purchase shares of Common Stock (a \"Company Option\"), whether or not vested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Merger Consideration over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger.  At the effective time of the Merger, each Company Option that is then outstanding and unexercised, whether or not vested and which has a per share exercise price that is equal to or greater than the Merger Consideration, shall be cancelled with no consideration payable therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, each unexercised and outstanding option to purchase shares of Common Stock (a \"Company Option\"), whether or not vested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Merger Consideration over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger.  At the effective time of the Merger, each Company Option that is then outstanding and unexercised, whether or not vested and which has a per share exercise price that is equal to or greater than the Merger Consideration, shall be cancelled with no consideration payable therefor."}],"balance_after":0,"derivative":{"exercise_price":21.5,"expiration_date":"2028-12-19","underlying":"Common Stock","underlying_shares":16866},"source":{"system":"sec-edgar","filing":"0001612842-26-000011","document":"form4-08272026_080801.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1419041/000161284226000011/form4-08272026_080801.xml","form_type":"4"}},{"id":673695,"issuer":{"id":9529,"kind":"organization","name":"Forte Biosciences, Inc."},"owners":[{"id":19059,"kind":"person","name":"Wagner Paul A.","position":1,"cik":"0001612842","reported_name":"Wagner Paul A.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SEE REMARKS"}}],"security":"Common Stock","published_at":"2026-08-27T20:28:06.000Z","date":"2026-08-27","kind":"other","planned":false,"acquired":false,"shares":85482,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated July 26, 2026 (the \"Merger Agreement\"), by and among Forte Biosciences, Inc. (\"Company\"), argenx BV (\"Parent\"), and Avena Merger Sub Inc., a wholly owned subsidiary of Parent (\"Purchaser\"), the shares of common stock of Company that were tendered to Purchaser prior to the expiration time of the offer were exchanged for $77.00 per share (\"Merger Consideration\"), net to the seller in cash, without interest, subject to any required withholding tax. After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into Company (the \"Merger\"), with Company surviving the Merger as a wholly owned subsidiary of Parent."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001612842-26-000011","document":"form4-08272026_080801.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1419041/000161284226000011/form4-08272026_080801.xml","form_type":"4"}},{"id":714982,"issuer":{"id":9529,"kind":"organization","name":"Forte Biosciences, Inc."},"owners":[{"id":19058,"kind":"person","name":"Riley Antony A","position":1,"cik":"0001339375","reported_name":"Riley Antony A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Restricted Stock Units","published_at":"2026-07-06T20:04:54.000Z","date":"2026-07-01","kind":"exercise","planned":false,"acquired":false,"shares":375,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Forte Biosciences, Inc. (the \"Issuer\") Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2021 Equity Incentive Plan) through each applicable vesting date, one-sixteenth (1/16th) of the RSUs subject to the award shall vest on each Quarterly Vesting Date (as defined below) on or immediately following February 1, 2023. For purposes of this RSU Award, \"Quarterly Vesting Date\" with respect to any calendar year means January 1, April 1, July 1, and October 1."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2021 Equity Incentive Plan) through each applicable vesting date, one-sixteenth (1/16th) of the RSUs subject to the award shall vest on each Quarterly Vesting Date (as defined below) on or immediately following February 1, 2023. For purposes of this RSU Award, \"Quarterly Vesting Date\" with respect to any calendar year means January 1, April 1, July 1, and October 1."}],"balance_after":750,"derivative":{"underlying":"Common Stock","underlying_shares":375},"source":{"system":"sec-edgar","filing":"0001339375-26-000010","document":"form4-07062026_080743.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1419041/000133937526000010/form4-07062026_080743.xml","form_type":"4"}},{"id":714981,"issuer":{"id":9529,"kind":"organization","name":"Forte Biosciences, Inc."},"owners":[{"id":19058,"kind":"person","name":"Riley Antony A","position":1,"cik":"0001339375","reported_name":"Riley Antony A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2026-07-06T20:04:54.000Z","date":"2026-07-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":134,"price":21.32,"value":2856.88,"ownership":{"direct":true},"balance_after":42600,"source":{"system":"sec-edgar","filing":"0001339375-26-000010","document":"form4-07062026_080743.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1419041/000133937526000010/form4-07062026_080743.xml","form_type":"4"}},{"id":714980,"issuer":{"id":9529,"kind":"organization","name":"Forte Biosciences, Inc."},"owners":[{"id":19058,"kind":"person","name":"Riley Antony A","position":1,"cik":"0001339375","reported_name":"Riley Antony A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2026-07-06T20:04:54.000Z","date":"2026-07-01","kind":"exercise","planned":false,"acquired":true,"shares":375,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Forte Biosciences, Inc. (the \"Issuer\") Common Stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 377 shares of Common Stock acquired July 1, 2026 under the Issuer's 2017 Employee Stock Purchase Plan."}],"balance_after":42734,"source":{"system":"sec-edgar","filing":"0001339375-26-000010","document":"form4-07062026_080743.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1419041/000133937526000010/form4-07062026_080743.xml","form_type":"4"}},{"id":714979,"issuer":{"id":9529,"kind":"organization","name":"Forte Biosciences, Inc."},"owners":[{"id":19059,"kind":"person","name":"Wagner Paul A.","position":1,"cik":"0001612842","reported_name":"Wagner Paul A.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SEE REMARKS"}}],"security":"Restricted Stock Units","published_at":"2026-07-06T20:03:25.000Z","date":"2026-07-01","kind":"exercise","planned":false,"acquired":false,"shares":1250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Forte Biosciences, Inc. (the \"Issuer\") Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2021 Equity Incentive Plan) through each applicable vesting date, one-sixteenth (1/16th) of the RSUs subject to the award shall vest on each Quarterly Vesting Date (as defined below) on or immediately following February 1, 2023. For purposes of this RSU Award, \"Quarterly Vesting Date\" with respect to any calendar year means January 1, April 1, July 1, and October 1."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2021 Equity Incentive Plan) through each applicable vesting date, one-sixteenth (1/16th) of the RSUs subject to the award shall vest on each Quarterly Vesting Date (as defined below) on or immediately following February 1, 2023. For purposes of this RSU Award, \"Quarterly Vesting Date\" with respect to any calendar year means January 1, April 1, July 1, and October 1."}],"balance_after":2500,"derivative":{"underlying":"Common Stock","underlying_shares":1250},"source":{"system":"sec-edgar","filing":"0001612842-26-000010","document":"form4-07062026_080721.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1419041/000161284226000010/form4-07062026_080721.xml","form_type":"4"}},{"id":714978,"issuer":{"id":9529,"kind":"organization","name":"Forte Biosciences, Inc."},"owners":[{"id":19059,"kind":"person","name":"Wagner Paul A.","position":1,"cik":"0001612842","reported_name":"Wagner Paul A.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SEE REMARKS"}}],"security":"Common Stock","published_at":"2026-07-06T20:03:25.000Z","date":"2026-07-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":98,"price":21.32,"value":2089.36,"ownership":{"direct":true},"balance_after":85482,"source":{"system":"sec-edgar","filing":"0001612842-26-000010","document":"form4-07062026_080721.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1419041/000161284226000010/form4-07062026_080721.xml","form_type":"4"}},{"id":714977,"issuer":{"id":9529,"kind":"organization","name":"Forte Biosciences, Inc."},"owners":[{"id":19059,"kind":"person","name":"Wagner Paul A.","position":1,"cik":"0001612842","reported_name":"Wagner Paul A.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SEE REMARKS"}}],"security":"Common Stock","published_at":"2026-07-06T20:03:25.000Z","date":"2026-07-01","kind":"exercise","planned":false,"acquired":true,"shares":1250,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Forte Biosciences, Inc. (the \"Issuer\") Common Stock."}],"balance_after":85580,"source":{"system":"sec-edgar","filing":"0001612842-26-000010","document":"form4-07062026_080721.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1419041/000161284226000010/form4-07062026_080721.xml","form_type":"4"}},{"id":733871,"issuer":{"id":9529,"kind":"organization","name":"Forte Biosciences, Inc."},"owners":[{"id":19058,"kind":"person","name":"Riley Antony A","position":1,"cik":"0001339375","reported_name":"Riley Antony A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Stock Option (right to buy)","published_at":"2026-06-17T20:55:43.000Z","date":"2026-06-16","kind":"grant","planned":false,"acquired":true,"shares":22000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2021 Equity Incentive Plan) through each applicable vesting date, one forty-eighth (1/48th) of the total shares subject to the option shall vest every month following the Vesting Commencement Date such that all shares shall be fully vested on the four (4) year anniversary of the Vesting Commencement Date. \"Vesting Commencement Date\" shall mean June 16, 2026."}],"balance_after":22000,"derivative":{"exercise_price":17.15,"expiration_date":"2036-06-16","underlying":"Common Stock","underlying_shares":22000},"source":{"system":"sec-edgar","filing":"0001339375-26-000008","document":"form4-06172026_080639.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1419041/000133937526000008/form4-06172026_080639.xml","form_type":"4"}},{"id":733869,"issuer":{"id":9529,"kind":"organization","name":"Forte Biosciences, Inc."},"owners":[{"id":19059,"kind":"person","name":"Wagner Paul A.","position":1,"cik":"0001612842","reported_name":"Wagner Paul A.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SEE REMARKS"}}],"security":"Stock Option (right to buy)","published_at":"2026-06-17T20:54:38.000Z","date":"2026-06-16","kind":"grant","planned":false,"acquired":true,"shares":500000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2021 Equity Incentive Plan) through each applicable vesting date, one forty-eighth (1/48th) of the total shares subject to the option shall vest every month following the Vesting Commencement Date such that all shares shall be fully vested on the four (4) year anniversary of the Vesting Commencement Date. \"Vesting Commencement Date\" shall mean June 16, 2026."}],"balance_after":500000,"derivative":{"exercise_price":17.15,"expiration_date":"2036-06-16","underlying":"Common Stock","underlying_shares":500000},"source":{"system":"sec-edgar","filing":"0001612842-26-000008","document":"form4-06172026_080634.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1419041/000161284226000008/form4-06172026_080634.xml","form_type":"4"}},{"id":754651,"issuer":{"id":9529,"kind":"organization","name":"Forte Biosciences, Inc."},"owners":[{"id":19076,"kind":"person","name":"Doberstein Stephen K","position":1,"cik":"0001480111","reported_name":"Doberstein Stephen K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2026-06-02T20:40:26.000Z","date":"2026-05-29","kind":"grant","planned":false,"acquired":true,"shares":18353,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Forte Biosciences, Inc. (the \"Issuer\") Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Subject to the Reporting Person's continuing as a Service Provider (as defined in the 2021 Equity Incentive Plan) through such date, one hundred percent (100%) of the RSUs subject to the award will vest on the date of the first annual meeting of the stockholders that occurs after May 29, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Subject to the Reporting Person's continuing as a Service Provider (as defined in the 2021 Equity Incentive Plan) through such date, one hundred percent (100%) of the RSUs subject to the award will vest on the date of the first annual meeting of the stockholders that occurs after May 29, 2026."}],"balance_after":18353,"derivative":{"underlying":"Common Stock","underlying_shares":18353},"source":{"system":"sec-edgar","filing":"0001480111-26-000002","document":"form4-06022026_080622.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1480111/000148011126000002/form4-06022026_080622.xml","form_type":"4"}},{"id":755321,"issuer":{"id":9529,"kind":"organization","name":"Forte Biosciences, Inc."},"owners":[{"id":19141,"kind":"person","name":"Kapoor Shivpreet Singh","position":1,"cik":"0002038311","reported_name":"Kapoor Shivpreet Singh","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2026-06-02T20:39:26.000Z","date":"2026-05-29","kind":"grant","planned":false,"acquired":true,"shares":18353,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Forte Biosciences, Inc. (the \"Issuer\") Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Subject to the Reporting Person's continuing as a Service Provider (as defined in the 2021 Equity Incentive Plan) through such date, one hundred percent (100%) of the RSUs subject to the award will vest on the date of the first annual meeting of the stockholders that occurs after May 29, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Subject to the Reporting Person's continuing as a Service Provider (as defined in the 2021 Equity Incentive Plan) through such date, one hundred percent (100%) of the RSUs subject to the award will vest on the date of the first annual meeting of the stockholders that occurs after May 29, 2026."}],"balance_after":18353,"derivative":{"underlying":"Common Stock","underlying_shares":18353},"source":{"system":"sec-edgar","filing":"0002038311-26-000002","document":"form4-06022026_080621.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2038311/000203831126000002/form4-06022026_080621.xml","form_type":"4"}},{"id":754516,"issuer":{"id":9529,"kind":"organization","name":"Forte Biosciences, Inc."},"owners":[{"id":19061,"kind":"person","name":"VINCENT RICHARD G","position":1,"cik":"0001269341","reported_name":"VINCENT RICHARD G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2026-06-02T20:38:26.000Z","date":"2026-05-29","kind":"grant","planned":false,"acquired":true,"shares":18353,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Forte Biosciences, Inc. (the \"Issuer\") Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Subject to the Reporting Person's continuing as a Service Provider (as defined in the 2021 Equity Incentive Plan) through such date, one hundred percent (100%) of the RSUs subject to the award will vest on the date of the first annual meeting of the stockholders that occurs after May 29, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Subject to the Reporting Person's continuing as a Service Provider (as defined in the 2021 Equity Incentive Plan) through such date, one hundred percent (100%) of the RSUs subject to the award will vest on the date of the first annual meeting of the stockholders that occurs after May 29, 2026."}],"balance_after":18353,"derivative":{"underlying":"Common Stock","underlying_shares":18353},"source":{"system":"sec-edgar","filing":"0001269341-26-000002","document":"form4-06022026_080621.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1419041/000126934126000002/form4-06022026_080621.xml","form_type":"4"}},{"id":754515,"issuer":{"id":9529,"kind":"organization","name":"Forte Biosciences, Inc."},"owners":[{"id":19062,"kind":"person","name":"GRYSKA DAVID W","position":1,"cik":"0001202335","reported_name":"GRYSKA DAVID W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2026-06-02T20:37:20.000Z","date":"2026-05-29","kind":"grant","planned":false,"acquired":true,"shares":18353,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Forte Biosciences, Inc. (the \"Issuer\") Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Subject to the Reporting Person's continuing as a Service Provider (as defined in the 2021 Equity Incentive Plan) through such date, one hundred percent (100%) of the RSUs subject to the award will vest on the date of the first annual meeting of the stockholders that occurs after May 29, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Subject to the Reporting Person's continuing as a Service Provider (as defined in the 2021 Equity Incentive Plan) through such date, one hundred percent (100%) of the RSUs subject to the award will vest on the date of the first annual meeting of the stockholders that occurs after May 29, 2026."}],"balance_after":18353,"derivative":{"underlying":"Common Stock","underlying_shares":18353},"source":{"system":"sec-edgar","filing":"0001202335-26-000002","document":"form4-06022026_080615.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1419041/000120233526000002/form4-06022026_080615.xml","form_type":"4"}},{"id":755097,"issuer":{"id":9529,"kind":"organization","name":"Forte Biosciences, Inc."},"owners":[{"id":19110,"kind":"person","name":"Brun Scott C.","position":1,"cik":"0001863614","reported_name":"Brun Scott C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2026-06-02T20:36:04.000Z","date":"2026-05-29","kind":"grant","planned":false,"acquired":true,"shares":18353,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Forte Biosciences, Inc. (the \"Issuer\") Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Subject to the Reporting Person's continuing as a Service Provider (as defined in the 2021 Equity Incentive Plan) through such date, one hundred percent (100%) of the RSUs subject to the award will vest on the date of the first annual meeting of the stockholders that occurs after May 29, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Subject to the Reporting Person's continuing as a Service Provider (as defined in the 2021 Equity Incentive Plan) through such date, one hundred percent (100%) of the RSUs subject to the award will vest on the date of the first annual meeting of the stockholders that occurs after May 29, 2026."}],"balance_after":18353,"derivative":{"underlying":"Common Stock","underlying_shares":18353},"source":{"system":"sec-edgar","filing":"0001863614-26-000002","document":"form4-06022026_080600.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863614/000186361426000002/form4-06022026_080600.xml","form_type":"4"}},{"id":754514,"issuer":{"id":9529,"kind":"organization","name":"Forte Biosciences, Inc."},"owners":[{"id":19063,"kind":"person","name":"Kornfeld Steven","position":1,"cik":"0001814653","reported_name":"Kornfeld Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2026-06-02T20:35:07.000Z","date":"2026-05-29","kind":"grant","planned":false,"acquired":true,"shares":18353,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Forte Biosciences, Inc. (the \"Issuer\") Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Subject to the Reporting Person's continuing as a Service Provider (as defined in the 2021 Equity Incentive Plan) through such date, one hundred percent (100%) of the RSUs subject to the award will vest on the date of the first annual meeting of the stockholders that occurs after May 29, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Subject to the Reporting Person's continuing as a Service Provider (as defined in the 2021 Equity Incentive Plan) through such date, one hundred percent (100%) of the RSUs subject to the award will vest on the date of the first annual meeting of the stockholders that occurs after May 29, 2026."}],"balance_after":18353,"derivative":{"underlying":"Common Stock","underlying_shares":18353},"source":{"system":"sec-edgar","filing":"0001814653-26-000002","document":"form4-06022026_080602.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1419041/000181465326000002/form4-06022026_080602.xml","form_type":"4"}},{"id":816099,"issuer":{"id":9529,"kind":"organization","name":"Forte Biosciences, Inc."},"owners":[{"id":19058,"kind":"person","name":"Riley Antony A","position":1,"cik":"0001339375","reported_name":"Riley Antony A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Restricted Stock Units","published_at":"2026-04-03T20:02:18.000Z","date":"2026-04-01","kind":"exercise","planned":false,"acquired":false,"shares":375,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Forte Biosciences, Inc. (the \"Issuer\") Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2021 Equity Incentive Plan) through each applicable vesting date, one-sixteenth (1/16th) of the RSUs subject to the award shall vest on each Quarterly Vesting Date (as defined below) on or immediately following February 1, 2023. For purposes of this RSU Award, \"Quarterly Vesting Date\" with respect to any calendar year means January 1, April 1, July 1, and October 1."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2021 Equity Incentive Plan) through each applicable vesting date, one-sixteenth (1/16th) of the RSUs subject to the award shall vest on each Quarterly Vesting Date (as defined below) on or immediately following February 1, 2023. For purposes of this RSU Award, \"Quarterly Vesting Date\" with respect to any calendar year means January 1, April 1, July 1, and October 1."}],"balance_after":1125,"derivative":{"underlying":"Common Stock","underlying_shares":375},"source":{"system":"sec-edgar","filing":"0001339375-26-000006","document":"form4-04032026_080413.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1419041/000133937526000006/form4-04032026_080413.xml","form_type":"4"}},{"id":816098,"issuer":{"id":9529,"kind":"organization","name":"Forte Biosciences, Inc."},"owners":[{"id":19058,"kind":"person","name":"Riley Antony A","position":1,"cik":"0001339375","reported_name":"Riley Antony A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2026-04-03T20:02:18.000Z","date":"2026-04-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":134,"price":24.86,"value":3331.24,"ownership":{"direct":true},"balance_after":41982,"source":{"system":"sec-edgar","filing":"0001339375-26-000006","document":"form4-04032026_080413.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1419041/000133937526000006/form4-04032026_080413.xml","form_type":"4"}},{"id":816097,"issuer":{"id":9529,"kind":"organization","name":"Forte Biosciences, Inc."},"owners":[{"id":19058,"kind":"person","name":"Riley Antony A","position":1,"cik":"0001339375","reported_name":"Riley Antony A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2026-04-03T20:02:18.000Z","date":"2026-04-01","kind":"exercise","planned":false,"acquired":true,"shares":375,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Forte Biosciences, Inc. (the \"Issuer\") Common Stock."}],"balance_after":42116,"source":{"system":"sec-edgar","filing":"0001339375-26-000006","document":"form4-04032026_080413.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1419041/000133937526000006/form4-04032026_080413.xml","form_type":"4"}},{"id":816096,"issuer":{"id":9529,"kind":"organization","name":"Forte Biosciences, Inc."},"owners":[{"id":19059,"kind":"person","name":"Wagner Paul A.","position":1,"cik":"0001612842","reported_name":"Wagner Paul A.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SEE REMARKS"}}],"security":"Restricted Stock Units","published_at":"2026-04-03T20:01:10.000Z","date":"2026-04-01","kind":"exercise","planned":false,"acquired":false,"shares":1250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Forte Biosciences, Inc. (the \"Issuer\") Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2021 Equity Incentive Plan) through each applicable vesting date, one-sixteenth (1/16th) of the RSUs subject to the award shall vest on each Quarterly Vesting Date (as defined below) on or immediately following February 1, 2023. For purposes of this RSU Award, \"Quarterly Vesting Date\" with respect to any calendar year means January 1, April 1, July 1, and October 1."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2021 Equity Incentive Plan) through each applicable vesting date, one-sixteenth (1/16th) of the RSUs subject to the award shall vest on each Quarterly Vesting Date (as defined below) on or immediately following February 1, 2023. For purposes of this RSU Award, \"Quarterly Vesting Date\" with respect to any calendar year means January 1, April 1, July 1, and October 1."}],"balance_after":3750,"derivative":{"underlying":"Common Stock","underlying_shares":1250},"source":{"system":"sec-edgar","filing":"0001612842-26-000006","document":"form4-04032026_080405.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1419041/000161284226000006/form4-04032026_080405.xml","form_type":"4"}},{"id":816095,"issuer":{"id":9529,"kind":"organization","name":"Forte Biosciences, Inc."},"owners":[{"id":19059,"kind":"person","name":"Wagner Paul A.","position":1,"cik":"0001612842","reported_name":"Wagner Paul A.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SEE REMARKS"}}],"security":"Common Stock","published_at":"2026-04-03T20:01:10.000Z","date":"2026-04-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":98,"price":24.86,"value":2436.28,"ownership":{"direct":true},"balance_after":84330,"source":{"system":"sec-edgar","filing":"0001612842-26-000006","document":"form4-04032026_080405.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1419041/000161284226000006/form4-04032026_080405.xml","form_type":"4"}},{"id":816094,"issuer":{"id":9529,"kind":"organization","name":"Forte Biosciences, Inc."},"owners":[{"id":19059,"kind":"person","name":"Wagner Paul A.","position":1,"cik":"0001612842","reported_name":"Wagner Paul A.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SEE REMARKS"}}],"security":"Common Stock","published_at":"2026-04-03T20:01:10.000Z","date":"2026-04-01","kind":"exercise","planned":false,"acquired":true,"shares":1250,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Forte Biosciences, Inc. (the \"Issuer\") Common Stock."}],"balance_after":84428,"source":{"system":"sec-edgar","filing":"0001612842-26-000006","document":"form4-04032026_080405.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1419041/000161284226000006/form4-04032026_080405.xml","form_type":"4"}},{"id":940010,"issuer":{"id":9529,"kind":"organization","name":"Forte Biosciences, Inc."},"owners":[{"id":19058,"kind":"person","name":"Riley Antony A","position":1,"cik":"0001339375","reported_name":"Riley Antony A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Restricted Stock Units","published_at":"2026-01-13T21:12:23.000Z","date":"2026-01-12","kind":"grant","planned":false,"acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Forte Biosciences, Inc. (the \"Issuer\") Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2021 Equity Incentive Plan) through each applicable vesting date, one fourth (1/4th) of the total RSUs subject to the award shall vest annually on the anniversary of Vesting Commencement Date such that all shares shall be fully vested on the four (4) year anniversary of the Vesting Commencement Date. \"Vesting Commencement Date\" shall mean January 1, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2021 Equity Incentive Plan) through each applicable vesting date, one fourth (1/4th) of the total RSUs subject to the award shall vest annually on the anniversary of Vesting Commencement Date such that all shares shall be fully vested on the four (4) year anniversary of the Vesting Commencement Date. \"Vesting Commencement Date\" shall mean January 1, 2026."}],"balance_after":60000,"derivative":{"underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001339375-26-000004","document":"form4-01132026_090120.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1419041/000133937526000004/form4-01132026_090120.xml","form_type":"4"}},{"id":940009,"issuer":{"id":9529,"kind":"organization","name":"Forte Biosciences, Inc."},"owners":[{"id":19058,"kind":"person","name":"Riley Antony A","position":1,"cik":"0001339375","reported_name":"Riley Antony A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Stock Option (right to buy)","published_at":"2026-01-13T21:12:23.000Z","date":"2026-01-12","kind":"grant","planned":false,"acquired":true,"shares":90000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2021 Equity Incentive Plan) through each applicable vesting date, one forty-eighth (1/48th) of the total shares subject to the option shall vest every month following the Vesting Commencement Date such that all shares shall be fully vested on the four (4) year anniversary of the Vesting Commencement Date. \"Vesting Commencement Date\" shall mean January 1, 2026."}],"balance_after":90000,"derivative":{"exercise_price":29.66,"expiration_date":"2036-01-12","underlying":"Common Stock","underlying_shares":90000},"source":{"system":"sec-edgar","filing":"0001339375-26-000004","document":"form4-01132026_090120.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1419041/000133937526000004/form4-01132026_090120.xml","form_type":"4"}},{"id":940005,"issuer":{"id":9529,"kind":"organization","name":"Forte Biosciences, Inc."},"owners":[{"id":19059,"kind":"person","name":"Wagner Paul A.","position":1,"cik":"0001612842","reported_name":"Wagner Paul A.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SEE REMARKS"}}],"security":"Restricted Stock Units","published_at":"2026-01-13T21:10:12.000Z","date":"2026-01-12","kind":"grant","planned":false,"acquired":true,"shares":180000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Forte Biosciences, Inc. (the \"Issuer\") Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2021 Equity Incentive Plan) through each applicable vesting date, one fourth (1/4th) of the total RSUs subject to the award shall vest annually on the anniversary of Vesting Commencement Date such that all shares shall be fully vested on the four (4) year anniversary of the Vesting Commencement Date. \"Vesting Commencement Date\" shall mean January 1, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2021 Equity Incentive Plan) through each applicable vesting date, one fourth (1/4th) of the total RSUs subject to the award shall vest annually on the anniversary of Vesting Commencement Date such that all shares shall be fully vested on the four (4) year anniversary of the Vesting Commencement Date. \"Vesting Commencement Date\" shall mean January 1, 2026."}],"balance_after":180000,"derivative":{"underlying":"Common Stock","underlying_shares":180000},"source":{"system":"sec-edgar","filing":"0001612842-26-000004","document":"form4-01132026_090104.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1419041/000161284226000004/form4-01132026_090104.xml","form_type":"4"}},{"id":940004,"issuer":{"id":9529,"kind":"organization","name":"Forte Biosciences, Inc."},"owners":[{"id":19059,"kind":"person","name":"Wagner Paul A.","position":1,"cik":"0001612842","reported_name":"Wagner Paul A.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SEE REMARKS"}}],"security":"Stock Option (right to buy)","published_at":"2026-01-13T21:10:12.000Z","date":"2026-01-12","kind":"grant","planned":false,"acquired":true,"shares":270000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2021 Equity Incentive Plan) through each applicable vesting date, one forty-eighth (1/48th) of the total shares subject to the option shall vest every month following the Vesting Commencement Date such that all shares shall be fully vested on the four (4) year anniversary of the Vesting Commencement Date. \"Vesting Commencement Date\" shall mean January 1, 2026."}],"balance_after":270000,"derivative":{"exercise_price":29.66,"expiration_date":"2036-01-12","underlying":"Common Stock","underlying_shares":270000},"source":{"system":"sec-edgar","filing":"0001612842-26-000004","document":"form4-01132026_090104.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1419041/000161284226000004/form4-01132026_090104.xml","form_type":"4"}},{"id":955099,"issuer":{"id":9529,"kind":"organization","name":"Forte Biosciences, Inc."},"owners":[{"id":19059,"kind":"person","name":"Wagner Paul A.","position":1,"cik":"0001612842","reported_name":"Wagner Paul A.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SEE REMARKS"}}],"security":"Restricted Stock Units","published_at":"2026-01-02T21:07:50.000Z","date":"2026-01-01","kind":"exercise","planned":false,"acquired":false,"shares":1250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Forte Biosciences, Inc. (the \"Issuer\") Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2021 Equity Incentive Plan) through each applicable vesting date, one-sixteenth (1/16th) of the RSUs subject to the award shall vest on each Quarterly Vesting Date (as defined below) on or immediately following February 1, 2023. For purposes of this RSU Award, \"Quarterly Vesting Date\" with respect to any calendar year means January 1, April 1, July 1, and October 1."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2021 Equity Incentive Plan) through each applicable vesting date, one-sixteenth (1/16th) of the RSUs subject to the award shall vest on each Quarterly Vesting Date (as defined below) on or immediately following February 1, 2023. For purposes of this RSU Award, \"Quarterly Vesting Date\" with respect to any calendar year means January 1, April 1, July 1, and October 1."}],"balance_after":5000,"derivative":{"underlying":"Common Stock","underlying_shares":1250},"source":{"system":"sec-edgar","filing":"0001612842-26-000002","document":"form4-01022026_090147.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1419041/000161284226000002/form4-01022026_090147.xml","form_type":"4"}},{"id":955098,"issuer":{"id":9529,"kind":"organization","name":"Forte Biosciences, Inc."},"owners":[{"id":19059,"kind":"person","name":"Wagner Paul A.","position":1,"cik":"0001612842","reported_name":"Wagner Paul A.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SEE REMARKS"}}],"security":"Common Stock","published_at":"2026-01-02T21:07:50.000Z","date":"2026-01-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":164,"price":27.27,"value":4472.28,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On January 1, 2026, the Reporting Person's RSUs vested. The closing price of the Issuer's Common Stock on December 31, 2025 was the settlement price used to calculate the shares withheld."}],"balance_after":83178,"source":{"system":"sec-edgar","filing":"0001612842-26-000002","document":"form4-01022026_090147.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1419041/000161284226000002/form4-01022026_090147.xml","form_type":"4"}},{"id":955097,"issuer":{"id":9529,"kind":"organization","name":"Forte Biosciences, Inc."},"owners":[{"id":19059,"kind":"person","name":"Wagner Paul A.","position":1,"cik":"0001612842","reported_name":"Wagner Paul A.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SEE REMARKS"}}],"security":"Common Stock","published_at":"2026-01-02T21:07:50.000Z","date":"2026-01-01","kind":"exercise","planned":false,"acquired":true,"shares":1250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Forte Biosciences, Inc. (the \"Issuer\") Common Stock."}],"balance_after":83342,"source":{"system":"sec-edgar","filing":"0001612842-26-000002","document":"form4-01022026_090147.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1419041/000161284226000002/form4-01022026_090147.xml","form_type":"4"}},{"id":955096,"issuer":{"id":9529,"kind":"organization","name":"Forte Biosciences, Inc."},"owners":[{"id":19058,"kind":"person","name":"Riley Antony A","position":1,"cik":"0001339375","reported_name":"Riley Antony A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Restricted Stock Units","published_at":"2026-01-02T21:04:43.000Z","date":"2026-01-01","kind":"exercise","planned":false,"acquired":false,"shares":375,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Forte Biosciences, Inc. (the \"Issuer\") Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2021 Equity Incentive Plan) through each applicable vesting date, one-sixteenth (1/16th) of the RSUs subject to the award shall vest on each Quarterly Vesting Date (as defined below) on or immediately following February 1, 2023. For purposes of this RSU Award, \"Quarterly Vesting Date\" with respect to any calendar year means January 1, April 1, July 1, and October 1."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2021 Equity Incentive Plan) through each applicable vesting date, one-sixteenth (1/16th) of the RSUs subject to the award shall vest on each Quarterly Vesting Date (as defined below) on or immediately following February 1, 2023. For purposes of this RSU Award, \"Quarterly Vesting Date\" with respect to any calendar year means January 1, April 1, July 1, and October 1."}],"balance_after":1500,"derivative":{"underlying":"Common Stock","underlying_shares":375},"source":{"system":"sec-edgar","filing":"0001339375-26-000002","document":"form4-01022026_090140.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1419041/000133937526000002/form4-01022026_090140.xml","form_type":"4"}},{"id":955095,"issuer":{"id":9529,"kind":"organization","name":"Forte Biosciences, Inc."},"owners":[{"id":19058,"kind":"person","name":"Riley Antony A","position":1,"cik":"0001339375","reported_name":"Riley Antony A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2026-01-02T21:04:43.000Z","date":"2026-01-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":154,"price":27.27,"value":4199.58,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On January 1, 2026, the Reporting Person's RSUs vested. The closing price of the Issuer's Common Stock on December 31, 2025 was the settlement price used to calculate the shares withheld."}],"balance_after":41741,"source":{"system":"sec-edgar","filing":"0001339375-26-000002","document":"form4-01022026_090140.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1419041/000133937526000002/form4-01022026_090140.xml","form_type":"4"}},{"id":955094,"issuer":{"id":9529,"kind":"organization","name":"Forte Biosciences, Inc."},"owners":[{"id":19058,"kind":"person","name":"Riley Antony A","position":1,"cik":"0001339375","reported_name":"Riley Antony A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2026-01-02T21:04:43.000Z","date":"2026-01-01","kind":"exercise","planned":false,"acquired":true,"shares":375,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Forte Biosciences, Inc. (the \"Issuer\") Common Stock."}],"balance_after":41895,"source":{"system":"sec-edgar","filing":"0001339375-26-000002","document":"form4-01022026_090140.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1419041/000133937526000002/form4-01022026_090140.xml","form_type":"4"}},{"id":955093,"issuer":{"id":9529,"kind":"organization","name":"Forte Biosciences, Inc."},"owners":[{"id":19058,"kind":"person","name":"Riley Antony A","position":1,"cik":"0001339375","reported_name":"Riley Antony A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2026-01-02T21:04:43.000Z","date":"2025-12-30","kind":"purchase","planned":false,"acquired":true,"shares":9680,"price":26.3257,"value":254832.776,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents the weighted average share price of an aggregate total of 9,680 shares purchased in the price range of $26.2243 to $26.59 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price."}],"balance_after":41520,"source":{"system":"sec-edgar","filing":"0001339375-26-000002","document":"form4-01022026_090140.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1419041/000133937526000002/form4-01022026_090140.xml","form_type":"4"}},{"id":1027034,"issuer":{"id":9529,"kind":"organization","name":"Forte Biosciences, Inc."},"owners":[{"id":19058,"kind":"person","name":"Riley Antony A","position":1,"cik":"0001339375","reported_name":"Riley Antony A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Restricted Stock Units","published_at":"2025-10-02T20:10:10.000Z","date":"2025-10-01","kind":"exercise","planned":false,"acquired":false,"shares":375,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Forte Biosciences, Inc. (the \"Issuer\") Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2021 Equity Incentive Plan) through each applicable vesting date, one-sixteenth (1/16th) of the RSUs subject to the award shall vest on each Quarterly Vesting Date (as defined below) on or immediately following February 1, 2023. For purposes of this RSU Award, \"Quarterly Vesting Date\" with respect to any calendar year means January 1, April 1, July 1, and October 1."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2021 Equity Incentive Plan) through each applicable vesting date, one-sixteenth (1/16th) of the RSUs subject to the award shall vest on each Quarterly Vesting Date (as defined below) on or immediately following February 1, 2023. For purposes of this RSU Award, \"Quarterly Vesting Date\" with respect to any calendar year means January 1, April 1, July 1, and October 1."}],"balance_after":1875,"derivative":{"underlying":"Common Stock","underlying_shares":375},"source":{"system":"sec-edgar","filing":"0001339375-25-000003","document":"form4-10022025_081004.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1419041/000133937525000003/form4-10022025_081004.xml","form_type":"4"}},{"id":1027033,"issuer":{"id":9529,"kind":"organization","name":"Forte Biosciences, Inc."},"owners":[{"id":19058,"kind":"person","name":"Riley Antony A","position":1,"cik":"0001339375","reported_name":"Riley Antony A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2025-10-02T20:10:10.000Z","date":"2025-10-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":134,"price":14.52,"value":1945.68,"ownership":{"direct":true},"balance_after":31840,"source":{"system":"sec-edgar","filing":"0001339375-25-000003","document":"form4-10022025_081004.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1419041/000133937525000003/form4-10022025_081004.xml","form_type":"4"}},{"id":1027032,"issuer":{"id":9529,"kind":"organization","name":"Forte Biosciences, Inc."},"owners":[{"id":19058,"kind":"person","name":"Riley Antony A","position":1,"cik":"0001339375","reported_name":"Riley Antony A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2025-10-02T20:10:10.000Z","date":"2025-10-01","kind":"exercise","planned":false,"acquired":true,"shares":375,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Forte Biosciences, Inc. (the \"Issuer\") Common Stock."}],"balance_after":31974,"source":{"system":"sec-edgar","filing":"0001339375-25-000003","document":"form4-10022025_081004.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1419041/000133937525000003/form4-10022025_081004.xml","form_type":"4"}},{"id":1027037,"issuer":{"id":9529,"kind":"organization","name":"Forte Biosciences, Inc."},"owners":[{"id":19059,"kind":"person","name":"Wagner Paul A.","position":1,"cik":"0001612842","reported_name":"Wagner Paul A.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SEE REMARKS"}}],"security":"Restricted Stock Units","published_at":"2025-10-02T20:09:17.000Z","date":"2025-10-01","kind":"exercise","planned":false,"acquired":false,"shares":1250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Forte Biosciences, Inc. (the \"Issuer\") Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2021 Equity Incentive Plan) through each applicable vesting date, one-sixteenth (1/16th) of the RSUs subject to the award shall vest on each Quarterly Vesting Date (as defined below) on or immediately following February 1, 2023. For purposes of this RSU Award, \"Quarterly Vesting Date\" with respect to any calendar year means January 1, April 1, July 1, and October 1."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2021 Equity Incentive Plan) through each applicable vesting date, one-sixteenth (1/16th) of the RSUs subject to the award shall vest on each Quarterly Vesting Date (as defined below) on or immediately following February 1, 2023. For purposes of this RSU Award, \"Quarterly Vesting Date\" with respect to any calendar year means January 1, April 1, July 1, and October 1."}],"balance_after":6250,"derivative":{"underlying":"Common Stock","underlying_shares":1250},"source":{"system":"sec-edgar","filing":"0001612842-25-000003","document":"form4-10022025_081009.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1419041/000161284225000003/form4-10022025_081009.xml","form_type":"4"}},{"id":1027036,"issuer":{"id":9529,"kind":"organization","name":"Forte Biosciences, Inc."},"owners":[{"id":19059,"kind":"person","name":"Wagner Paul A.","position":1,"cik":"0001612842","reported_name":"Wagner Paul A.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SEE REMARKS"}}],"security":"Common Stock","published_at":"2025-10-02T20:09:17.000Z","date":"2025-10-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":98,"price":14.52,"value":1422.96,"ownership":{"direct":true},"balance_after":82092,"source":{"system":"sec-edgar","filing":"0001612842-25-000003","document":"form4-10022025_081009.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1419041/000161284225000003/form4-10022025_081009.xml","form_type":"4"}},{"id":1027035,"issuer":{"id":9529,"kind":"organization","name":"Forte Biosciences, Inc."},"owners":[{"id":19059,"kind":"person","name":"Wagner Paul A.","position":1,"cik":"0001612842","reported_name":"Wagner Paul A.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SEE REMARKS"}}],"security":"Common Stock","published_at":"2025-10-02T20:09:17.000Z","date":"2025-10-01","kind":"exercise","planned":false,"acquired":true,"shares":1250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Forte Biosciences, Inc. (the \"Issuer\") Common Stock."}],"balance_after":82190,"source":{"system":"sec-edgar","filing":"0001612842-25-000003","document":"form4-10022025_081009.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1419041/000161284225000003/form4-10022025_081009.xml","form_type":"4"}},{"id":1092167,"issuer":{"id":9529,"kind":"organization","name":"Forte Biosciences, Inc."},"owners":[{"id":19058,"kind":"person","name":"Riley Antony A","position":1,"cik":"0001339375","reported_name":"Riley Antony A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Restricted Stock Units","published_at":"2025-07-03T20:22:07.000Z","date":"2025-07-01","kind":"exercise","planned":false,"acquired":false,"shares":375,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Forte Biosciences, Inc. (the \"Issuer\") Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2021 Equity Incentive Plan) through each applicable vesting date, one-sixteenth (1/16th) of the RSUs subject to the award shall vest on each Quarterly Vesting Date (as defined below) on or immediately following February 1, 2023. For purposes of this RSU Award, \"Quarterly Vesting Date\" with respect to any calendar year means January 1, April 1, July 1, and October 1."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2021 Equity Incentive Plan) through each applicable vesting date, one-sixteenth (1/16th) of the RSUs subject to the award shall vest on each Quarterly Vesting Date (as defined below) on or immediately following February 1, 2023. For purposes of this RSU Award, \"Quarterly Vesting Date\" with respect to any calendar year means January 1, April 1, July 1, and October 1."}],"balance_after":2250,"derivative":{"underlying":"Common Stock","underlying_shares":375},"source":{"system":"sec-edgar","filing":"0001415889-25-019322","document":"form4-07032025_080704.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1419041/000141588925019322/form4-07032025_080704.xml","form_type":"4"}}],"next_cursor":"2025-07-03T20:22:07.000000Z,1092167"}